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The Swiss Childhood Cancer Registry (SCCR) is the national 
population - based cancer registry for children and adolescents 
in Switzerland. New cancer diagnoses, clinical information, de-
tails on treatment and long - term follow - up (survival, second 
primary neoplasms and late effects) have been registered in 
the SCCR since 1976. This year, 2016, the SCCR celebrates 
its 40th birthday! With many associated research projects and 
through close collaboration with clinicians it contributes to 
understanding the causes of cancer in children, improving fol-
low - up care and reducing late effects.
The SCCR is located at the Institute of Social and Preven-
tive Medicine (ISPM) at the University of Bern. It is operated 
jointly by the Swiss Paediatric Oncology Group (SPOG) and the 
University of Bern. Since 1976, all nine Swiss paediatric haema-
tology - oncology centres report newly diagnosed cases to the 
registry and send annual updates on clinical follow - up. Since 
2007, the SCCR also collects supplementary data from other 
sources, including cantonal cancer registries, other hospitals, 
pathology laboratories and the Swiss Federal Statistical Office 
(SFSO). As of 31st December 2014, data from 9353 cases (diag-
nosed in 9225 patients) have been registered. 
The SCCR is authorized to collect non - anonymised data. 
The permission has been issued in 2007 by the Federal Com-
mission of Experts for Professional Secrecy in Medical Research 
(Eidgenössische Expertenkommission für das Berufsgeheimnis 
in der medizinischen Forschung). Since 2014 the new act on 
human research is in place. The SCCR got a new authorization 
issued by the ethics committee of the canton of Bern in July 
2014.
The SCCR is an associated member of the National In-
stitute for Cancer Epidemiology and Registration (NICER), of 
the European Network of Cancer Registries (ENCR) and of the 
International Association of Cancer Registries (IACR), and col-
laborates with childhood cancer registries throughout Europe.
What did the Swiss Childhood Cancer Registry achieve 
in 40 years?
 • Performed national childhood cancer monitoring of high 
quality
 • Provided reliable statistical routine data
 • Established a competitive research platform
 • Gave competent ad hoc answers to health- , environmental- , 
  socio- , political- related questions
 • Cooperated closely with all paediatric oncologists, 
 • Established a strong network with Swiss parents organi-
sations
This seventh report covers the routine analyses of all chil-
dren diagnosed between 1st January 1976 and 31st December 
2014. Activities, research and publications of the SCCR are de-
scribed for the years 2014 to 2016. The report contains:
• An overview of the organisation and team of the SCCR, 
SPOG and the participating paediatric haematology - 
  oncology centres (Chapter 2)
• A summary of the data collected in the registry up to 31st 
December 2014 (Chapter 3)
• A summary of current research of the SCCR  (Chapter 4)
• A list of publications (Chapter 5)
Our website (www.childhoodcancerregistry.ch) contains 
further information, including past annual reports and scien-
tific publications.
We would like to thank all the children and their families, 
and all adolescent and adult childhood cancer survivors, for 
allowing us to collect their data. We also thank the physicians 
and clinical research coordinators of the Swiss Paediatric On-
cology Group for their excellent collaboration. Our thanks also 
go to the cantonal cancer registries, the National Institute for 
Cancer Epidemiology and Registration (NICER), the Swiss Fed-
eral Statistical Office (SFSO), the Federal Office of Public Health 
(FOPH) and the pathology laboratories for their cooperation. 
Finally, we thank our supporters for their generous contribu-
tions.
1. Introduction
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2. Organisation of the Swiss Childhood Cancer Registry
The Swiss Childhood Cancer Registry (SCCR) is a member of the Swiss Paediatric Oncology Group (SPOG) and is or-
ganised as a joint operation of the Institute of Social and Preventive Medicine (ISPM) at the University of Bern and the 
SPOG.
2.1 Institute of Social and Preventive Medicine (ISPM), University of Bern
Direction
Claudia Kuehni, Prof MD Head of SCCR claudia.kuehni@ispm.unibe.ch
Gisela Michel, Prof PhD Vice head of SCCR gisela.michel@unilu.ch
 
Swiss Childhood Cancer Registry
Verena Pfeiffer, PhD Project coordinator SCCR verena.pfeiffer@ispm.unibe.ch
Katharina Flandera Administration katharina.flandera@ispm.unibe.ch
Shelagh Redmond, PhD Diagnostic coding, data quality
Parvinder Singh Statistics 
Meltem Altun Data management 
Erika Brantschen Data management 
 
Trust Centre 
Christina Krenger Data management 
 
Informatics and database support 
Priska Wölfli Database support 
 
Research projects 
Ben Spycher, PhD Senior research fellow, Project manager
Grit Sommer, PhD Senior research fellow, Project manager
Rahel Kuonen, MSc Senior research fellow, Project manager
Christian Kreis, PhD Senior research fellow
Fabien Belle, MSc PhD student
Konstantinoudis Garyfallos, MSc PhD student
Rahel Kasteler, MD PhD student
Matthias Schindler, MSc PhD student
Annette Weiss, MSc PhD student
Swiss Childhood Cancer Registry
Institute of 
Social and Preventive Medicine
Finkenhubelweg 11
CH - 3012 Bern
Switzerland
Tel. +41 (0)31 631 56 70
www.childhoodcancerregistry.ch
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2.2 Swiss Paediatric Oncology Group (SPOG)
SPOG Executive Board 
Felix Niggli, Prof MD President 
Heinz Hengartner, MD Vice president 
Maja Beck Popovic, Prof MD Committee Member 
SPOG Office in Bern 
Isabelle Lamontagne - Müller, MSc Managing director isabelle.lamontagne@spog.ch
Marlise Rohrer Director’s assistant 
Barbara Böttcher, PhD Head Quality assurance  
Julia Ruckstuhl, MSc Head Regulatory affairs 
Tu- My Diep Lai, PhD Regulatory affairs 
Martina Peluso, MSc Regulatory affairs  
Silvia Wirth, PhD Quality assurance   
  Regulatory affairs 
 
Participating centres (paediatric haematology - oncology)
  Head of Division Clinical Research Coordinator
Aarau 
Kinderklinik, Kantonsspital Aarau R. Angst, MD C. Anderegg, MSc
Basel 
Universitäts - Kinderspital  N. von der Weid, Prof MD V. Stahel
beider Basel [UKBB]  M. Imbach
Bern 
Universitätsklinik für  K. Leibundgut, Prof MD F. Julmy 
Kinderheilkunde, Inselspital  N. Beusch
Genève 
Hôpital des Enfants, Hôpitaux  M. Ansari, Prof MD R. Lo Piccolo
Universitaires de Genève [HUG]  V. Mattiello, MD
Lausanne 
Service de Pédiatrie, Centre Hospitalier  M. Beck Popovic, Prof MD R. - E. Garcia, MD
Universitaire Vaudois [CHUV]  E. Lemmel
Bellinzona 
Reparto di Pediatria, Ospedale  P. Brazzola, MD P. Brazzola, MD
S. Giovanni, Bellinzona  P. Balestra
Luzern 
Kinderspital, Kantonsspital Luzern J. Rischewski, PD MD N. Lanz
St.Gallen 
Ostschweizer Kinderspital J. Greiner - Lang, MD F. Hochreutener
    A. Schiltknecht
Zürich  
Universitäts - Kinderspital, Zürich F. Niggli, Prof MD H. Markiewicz
  M. Grotzer, Prof MD A. Reinberg
   R. Siegenthaler
   C. Althaus, MD
SPOG Office 
Effingerstrasse 33, 3008 Bern
Tel.: +41 (0)31 508 42 33
www.spog.ch
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2.3 General information
Aims 
The Swiss Childhood Cancer Registry collects information 
on the diagnosis, treatment and follow- up of children and ad-
olescents with cancer in Switzerland, and provides data for na-
tional and international statistics and research projects. 
It aims: 
• To collect representative, population- based data on 
cancer in children and adolescents in Switzerland (cancer 
incidence, prevalence, time trends, regional distribution 
and survival rates)
• To document diagnostic evaluations, treatment and 
participation in clinical trials
• To describe short- term and long- term prognosis (mortali-
ty, morbidity and quality of life) after cancer in childhood 
and adolescence
• To provide a research platform for clinical, epidemiologi-
cal and basic research
It thus contributes to:
• Research into the aetiology of cancer in children and 
adolescents
• Planning of health services 
• Continuous improvement of treatment
• Identifying possible late effects of therapy, with the aim 
to diagnose and treat them early and prevent them in 
the future 
Inclusion criteria
The SCCR registers all children and adolescents aged 0 to 
20 years, resident or treated in Switzerland, diagnosed with:
• Acute and chronic leukaemias, including myelodysplastic 
syndrome
• Lymphomas
• Malignant solid tumours
• Central nervous system tumours (CNS), malignant and 
benign tumours 
• Langerhans cell histiocytosis (LCH), 
  Hemophagocytic lymphohistiocytosis (HLH) 
Since 2014 it also registers children and adolescents diagnosed 
with:
• Aggressive fibromatosis (ICD - O - 3M code 8821 /1)
• Benign /mature teratoma (ICD - O - 3M code 9080 /0)
• Mesoblastic nephroma (ICD - O - 3M code 8960 /1)
• Severe aplastic anaemia (ICD - 10 D61.9)
• Neoplasms of the liver, histologically proven, but no 
malformations
Children and adolescents who are not Swiss residents but 
are diagnosed or treated in Switzerland are registered, but they 
are excluded from analyses of incidence and survival.
Sources of data
 Data on children and adolescents with cancer are collect-
ed from several sources, including: 
• The nine Swiss centres for paediatric oncology and hae-
matology (Chapter 2.2)
• Other hospitals
• Cantonal cancer registries, represented by the National 
Institute for Cancer Epidemiology and Registration 
  (NICER)
• Clinical and epidemiological registries (e.g. brain tumour 
registry, bone tumour registry, Swiss growth registry etc.)
• The Swiss Federal Statistical Office (SFSO; Swiss mortality 
statistics)
• Pathology laboratories 
Most children are reported by one of the nine Swiss cen-
tres for paediatric oncology and haematology. Local clinical 
research coordinators complete forms for all newly diagnosed 
patients. Basic information on diagnosis is later completed with 
information on treatments, remissions, relapses, transplanta-
tions and health outcomes. These forms are sent to the SCCR 
and information is entered into the database. Important medi-
cal documents (e.g. pathology reports) are scanned and stored 
electronically using a pseudonym. Paper copies are destroyed. 
Information on Swiss residency is validated through municipal 
population registers.
For the first five to ten years after diagnosis follow- up data 
is extracted annually from patients’ hospital records by the lo-
cal clinical research coordinators in all paediatric oncology and 
haematology centres (Chapter 3.3). To assess outcomes after 
the children have left the clinic, patients are contacted directly 
with a questionnaire and data is linked to mortality records 
(SFSO) and to records from cantonal cancer registries (Chapter 
4.2). Life status update is assessed through community reg-
istries. For children not treated in a paediatric oncology and 
haematology centre, clinical follow- up from hospitals is often 
not available, but long- term epidemiological follow- up is done 
via questionnaires and by assessment of second primary neo-
plasms and mortality as for the other patients and life status 
update via community registries (Chapter 3.3).
Clinical database
 The current SCCR database was set up in 2007. The fol-
lowing information is routinely collected:
• Tumour diagnosis, date of diagnosis, morphology, to-
pography, stage, metastases
• Other diagnoses (cancer- relevant pre- existing conditions)
• Relevant laboratory and clinical data
• Treatment (clinical trial participation, chemotherapy, radio- 
  therapy, surgical intervention, bone marrow transplanta-
tion) and treatment centres involved
• Follow- up data (changes of treatment, remissions, re-
lapses, survival /death and cause of death)
• Late adverse outcomes (e.g. cardiovascular diseases, 
second primary neoplasms and endocrine disorders) 
12
Trust centre
Since 2010, personal information (name and address) is 
stored in a separate database in the trust centre. The trust cen-
tre validates addresses, residence status, nationality, and vital 
status via community registers. This personal information is 
separated strictly from clinical information of the SCCR data-
base. The following data is collected: 
• Patient name, address of residence at time of diagnosis, 
  current address of residence
• Date of birth, sex, first language
• Country of residence and nationality at time of diagnosis
• Vital status and date of death
• Parental profession, parental date of birth
Tumour coding
 All tumours are coded according to the following interna-
tional classification systems (see appendix): 
• International Classification of Childhood Cancer, third 
edition (ICCC - 3) 
• International Classification of Diseases for Oncology, 
third edition (ICD - O - 3) 
• International Classification of Diseases and Related 
Health Problems, tenth revision (ICD - 10) 
In the annual report, the main diagnostic groups of the ICCC - 3 
are used: 
I.  Leukaemias, myeloproliferative diseases, and myelodys- 
 plastic diseases
II.  Lymphomas and reticuloendothelial neoplasms
III.  CNS and miscellaneous intracranial and intraspinal 
 neoplasms
IV.  Neuroblastoma and other peripheral nervous cell tumours
V.  Retinoblastoma
VI. Renal tumours
VII. Hepatic tumours
VIII. Malignant bone tumours
IX.  Soft tissue and other extraosseous sarcomas
X. Germ cell tumours, trophoblastic tumours, and 
 neoplasms of gonads
XI.  Other malignant epithelial neoplasms and malignant   
 melanomas
XII. Other specified and unspecified malignant neoplasms 
Langerhans cell histiocytosis (LCH), which is not included in 
ICCC - 3, is reported separately.
Data protection
In 2004, the SCCR received a special authorisation (Son-
derbewilligung) from the Swiss Federal Commission of Experts 
for Professional Secrecy in Medical Research. Starting from 
June 2007, a general authorization (Registerbewilligung) ) per-
mitted the data collection from paediatric cancer patients (chil-
dren and adolescents) throughout Switzerland after obtaining 
written, oral or silent consent. 
Since January 2014 the new Human Research Act and its 
three ordinances are in place. Out of those three ordinances, 
the ordinance on Human Research with the exception of Clin-
ical Trials provides the new framework for the SCCR. Instead 
of the Swiss Federal Commission of Experts for Professional 
Secrecy in Medical Research, data collection and storage by 
SCCR now require an authorisation by the ethics committee of 
the canton of Bern. The general authorization (Registerbewilli-
gung) has been replaced in July 2014 by an approval from the 
ethics committee of the canton of Bern. 
Funding
The SCCR thanks the following supporters for their finan-
cial contributions towards the daily operation and the con-
tinuous development of the registry. Supporters of scientific 
research of the SCCR are listed in Chapter 4.
Main funding sources 2014 /2015
• Schweizerische Konferenz der kantonalen Gesundheits- 
  direktoren und - direktorinnen (GDK)
• Schweizerische Pädiatrische Onkologie Gruppe (SPOG) 
• Universität Bern, Institut für Sozial- und Präventivmedizin 
(ISPM)
• Krebsforschung Schweiz 
• Kinderkrebshilfe Schweiz  
Other funding sources 2014 /2015
• National Institute for Cancer Epidemiology and 
  Registration (NICER)
• Federal Office of Health (FOH)
• AXA- Winterthur
• Celgene GmbH 
  (through Förderverein Schweizer Kinderkrebsregister)
• Amgen Switzerland AG 
  (through Förderverein Schweizer Kinderkrebsregister)
• Helsana Versicherungen AG 
  (through Förderverein Schweizer Kinderkrebsregister)
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3.1 Overview
The SCCR registers all tumours diagnosed and treated in 
Switzerland, classified according to the ICCC - 3 and Langer-
hans cell histiocytosis (LCH) in patients aged 0 to 20 years at 
time of diagnosis. This annual report covers the time period 
from 1st January 1976 until 31st December 2014. The addi-
tional disorders, which are registered since 2014 (see inclusion 
criteria under paragraph 2.3), have not been included in the 
following analyses. Incidence rates are calculated based on the 
number of primary neoplasms (cases). The number of cases 
slightly exceeds the number of patients because patients with 
more than one primary tumour diagnosed before age 20 years 
are counted separately for each new tumour. 
The section on routine analyses includes three chapters:
Chapter 3.2 presents data on all cases registered in the 
SCCR. This includes cases resident in Switzerland or abroad, 
who were diagnosed or treated in Switzerland. 
Chapter 3.3 presents data on cases resident in Switzer-
land, aged 0 to 14 years at diagnosis. This correspondents to 
the age group usually covered in international publications. 
Therefore, tables and figures can be compared with data from 
other countries. Because registration in Switzerland is more 
than 95% complete for this age range with estimated inci-
dence and survival rates close to their true value.
Chapter 3.4 presents data on cases resident in Switzer-
land, aged 15 to 20 years at diagnosis. Patients of this age 
group are treated in a large number and variety of clinics and 
therefore registration is less complete. Ultimately, incidence 
rates cannot be calculated for this age group.
3.2 All cases registered in the SCCR (N = 9353)
This chapter describes data from all cases diagnosed 
1976 - 2014, resident in Switzerland or abroad, diagnosed or 
treated in Switzerland (N = 9353). 
Up to 31st December 2014, a total of 9353 cases classifi-
able according to the ICCC-3, or Langerhans cell histiocytosis 
(LCH), have been registered in the SCCR. These tumours were 
diagnosed in 9225 patients. Among these, 9099 patients had 
only one primary neoplasm, 124 patients had two primary 
neoplasms and 2 patients had three primary neoplasms at age 
0 - 20 years. 
The SCCR started in 1976. Initially, only patients aged 0 
to 15 years who participated in clinical trials were registered. 
Non- trial patients have been included since 1982, resulting 
in a significant increase in the number registered. In the early 
1990s, the introduction of the first electronic database further 
increased case registration. Since then, annual registration has 
remained constant (Figure 1).
In the last five years (2010 - 2014), a total of 1461 newly 
diagnosed cases were registered; among them 1278 cases in 
Swiss residents (Table 1).
Swiss residents account for 8317 (89%) of all cases and 
foreign residents for 1036 (11%) cases (Table 2). Swiss resi-
dents make up 38% (168 /447) of all retinoblastoma patients, 
while foreign residents make up 62% (279 /447) of these pa-
tients. This is due to the international reputation of the Jules 
Gonin Hospital in Lausanne, which is the national centre for 
retinoblastoma treatment but also attracts many patients from 
abroad.
3. Routine Analyses
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Figure 1
Annual number of 
registered cases over time
Swiss and foreign residents, age 
at diagnosis 0 - 14 years; period of 
diagnosis 1976 - 2014; all diagnoses 
(ICCC - 3 or Langerhans cell 
histiocytosis); N = 7504
14
 
  Age at diagnosis (years)
 All ages (0 - 20) Children (0 - 14) Adolescents (15 - 20)
Country of residence n % n % n %
Switzerland 8317 88,9 6604 88,0 1713 92,6
Foreign countries 1036 11,1 900 12,0 136 7,4
Europe  726 7,8 645 8,6 81 4,4
 • Neighbouring countries 405 4,3 351 4,7 54 2,9
  - Austria 10 0,1 10 0,1 0 0,0
  - France 141 1,5 110 1,5 31 1,7
  - Germany 79 0,8 74 1,0 5 0,3
  - Italy  174 1,9 156 2,1 18 1,0
  - Liechtenstein 1 0,0 1 0,0 0 0,0
 • Other European countries 321 3,4 294 3,9 27 1,5
Middle East 34 0,4 29 0,4 5 0,3
North Africa 152 1,6 122 1,6 30 1,6
Other African countries 48 0,5 41 0,5 7 0,4
All other countries 59 0,6 51 0,7 8 0,4
Abroad  17 0,2 12 0,2 5 0,3
TOTAL  9353 100,0 7504 100,0 1849 100,0
Swiss and foreign residents, age at diagnosis 0 - 20 years; period of diagnosis 1976 - 2013; all diagnoses (ICCC - 3 or 
Langerhans cell histiocytosis); N = 9353
Table 2 
Total number of cases 
registered in the SCCR, 
by country of residence
Table 1
Total number of 
cases registered in the 
SCCR, by period of 
diagnosis
   All patients Swiss residents Foreign  
   residents
   Age at Age at Age at 
   diagnosis diagnosis diagnosis  
 Year of diagnosis (years) (years) (years)
   0 - 14 15 - 20 0 - 14 15 - 20 0 - 14 15 - 20
  1976 - 1984 1151 267 1024 243 127 24
  1985 - 1989 864 231 730 213 134 18
  1990 - 1994 1080 253 934 231 146 22
  1995 - 1999 1043 294 930 268 113 26
  2000 - 2004 1072 279 999 257 73 22
  2005 - 2009 1061 297 931 279 130 18
  2010 - 2014 1233 228 1056 222 177 6
    7504 1849 6604 1713 900 136
Swiss and foreign residents, age at diagnosis 0 - 20 years; period of diagnosis 1976 - 2014; all diagnoses (ICCC - 3 or 
Langer hans cell histiocytosis); N = 9353
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3.3 Swiss residents aged 0 - 14 years 
 at diagnosis (N = 6604)
This chapter reports on cases aged 0 - 14 years and resi-
dent in Switzerland at diagnosis with a tumour coded accord-
ing to ICCC - 3 or a Langerhans cell histiocytosis. Results for 
this age group can be compared directly to data from other 
countries. 
Diagnoses
The International Classification of Childhood Cancer (ICCC - 3) 
distinguishes 12 groups of cancers (Table 3). The most com-
mon are leukaemias (33% of all cancers), followed by tumours 
of the central nervous system (20%; especially brain tumours); 
and lymphomas (12%). Other cancers arise from embryonic 
tissue. These include neuroblastoma (7%) from primitive neu-
ral tissue, nephroblastoma (5%) from renal tissue, hepatoblas-
toma (1%) in the liver, germ cell tumours (3%), and retinoblas-
toma (3%). 
Germ cell tumours may arise in the gonads (ovaries and 
testes), or in other sites, such as the brain (intracranial germ 
cell tumours). Soft tissue sarcomas (7%), and malignant bone 
tumours (4%) arise from abnormal connective tissue. Occa-
sionally, children also develop carcinomas such as melanomas 
or other rare tumours (3%). Langerhans cell histiocytosis (3%) 
is officially not counted as a malignant disease. But as children 
with this disease are treated similarly to those with cancer and 
in rare cases also die, they are recorded in the Swiss Childhood 
Cancer Registry. The relative frequency of the different tumour 
types varies with age (Table 3 and Figure 2). 
 All children By age at diagnosis (years)
  <1 1 - 4 5 - 9 10 - 14
Diagnosis      n % n % n % n % n %
I Leukaemias, myeoloproliferative diseases 
 and myelodysplastic diseases    2167 32,8 87 13,7 1039 45,0 605 34,2 436 23,1
II Lymphomas and reticuloendothelial neoplasms  814 12,3 22 3,5 130 5,6 228 12,9 434 23,0
III Central nervous system neoplasms   1318 20,0 73 11,5 375 16,2 488 27,6 382 20,2
IV Neuroblastoma and other peripheral 
 nervous cell tumours     432 6,5 185 29,1 194 8,4 34 1,9 19 1,0
V Retinoblastoma     167 2,5 78 12,3 80 3,5 8 0,5 1 0,1
VI Renal tumours     339 5,1 48 7,5 196 8,5 83 4,7 12 0,6
VII Hepatic tumours     62 0,9 20 3,1 25 1,1 7 0,4 10 0,5
VIII Malignant bone tumours    285 4,3 0 0,0 19 0,8 86 4,9 180 9,5
IX Soft tissue and other extraosseous sarcomas  443 6,7 47 7,4 127 5,5 111 6,3 158 8,4
X Germ cell tumours, trophoblastic tumours 
 and neoplasms of gonads    179 2,7 36 5,7 42 1,8 25 1,4 76 4,0
XI Other malignant epithelial neoplasms 
 and malignant melanomas    184 2,8 4 0,6 8 0,3 40 2,3 132 7,0
XII Other specified and unspecified malignant neoplasms 14 0,2 2 0,3 4 0,2 1 0,1 7 0,4
 Langerhans cell histiocytosis    200 3,0 34 5,3 71 3,1 54 3,1 41 2,2
 Total      6604 100,0 636 100,0 2310 100,0 1770 100,0 1888 100,0
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2014; all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 6604 
Table 3 Main diagnostic groups according to ICCC - 3, by age at diagnosis
16
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2014; all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); 
N = 6604
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Follow- up information
The SCCR collects follow- up information for patients in several 
ways: 
1. Clinical follow- up is any contact the patient has with 
the paediatric oncology and haematology centre. Annual 
clinical follow- up care in paediatric centres usually ends 
5 - 10 years after diagnosis. Then the patient is officially 
discharged or referred to an adult oncology centre. Alter-
natively clinical follow- up also ends as soon as the patient 
dies. 
2. Long- term epidemiological follow- up for vital status, 
subsequent neoplasms and current health employs four 
complementary approaches:
• Vital status and current address and place of birth are 
updated by contacting municipal population registers. 
Vital status is known for most cases: among the 6541 
patients, 1636 (25%) have died, and 4905 (75%) are 
still alive (Table 4). Among these, most (4608) have been 
followed- up during the past 5 years, 165 (3%) have last 
been followed up between 2004 and 2008, and only 
132 (3%) before 2004. Among the latter, 93 (32 be-
tween 2004 - 2008 and 61 before 2004) are lost to fol-
low- up, because they moved abroad. 
• Causes of death are retrieved from Swiss mortality sta-
tistics by record linkage.
• Second primary neoplasms are notified via paediatric 
oncology and haematology centres, detected by regular 
comparison with cantonal (regional) cancer registries in 
Switzerland, or self- reported by survivors and then vali-
dated with pathology reports.
• Morbidity and quality of life are assessed by paper 
questionnaires to survivors in the Swiss Childhood Can-
cer Survivor Study and Childhood Cancer Follow- up 
Study (Chapter 4.2).
Table 4 
Follow- up information available in the SCCR
    n %
Alive  4905 75.0
Last clinical follow- up after 2008 4608 93.9
Last clinical follow- up 2004 - 2008 165 3.4
Last clinical follow- up before 2004 132 2.7
Deceased  1636 25.0
TOTAL  6541 100.0
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2014; all 
diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 6541 patients (6604 cases)  
Figure 2 
Main diagnostic groups according to ICCC - 3, by age at diagnosis
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Figure 3 
Survival of patients in the SCCR, 
by period of diagnosis
Swiss residents; age at diagnosis 0 - 14 years; 
period of diagnosis 1976 - 2014; all diagnoses 
(ICCC - 3 or Langerhans cell histiocytosis); 
N = 6604; adjusted for age.
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Figure 4 
Survival of patients by diagnostic 
groups according to ICCC - 3
Swiss residents; age at diagnosis 0 - 14 years; 
period of diagnosis 1995 - 2014 all diagnoses 
(ICCC - 3 or Langerhans cell histiocytosis); 
N = 3916; adjusted for age.
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Survival
Long- term survival has improved significantly over the last 
decades (Figure 3).
Ten- year survival increased from 58% in children diag-
nosed between 1976 and 1984, to 71% in children diagnosed 
between 1985 and 1994, 80% in children diagnosed between 
1995 and 2004, and 87% in children diagnosed within the last 
decade (2005 - 2014). 
Survival varied widely between diagnostic groups. Figure 4
presents survival by diagnostic group according to ICCC - 3 in 
children diagnosed between 1995 and 2014. Of 3916 chil-
dren, 705 (18%) have died. The following numbers describe 
five- year survival for each main diagnostic group: 99% for 
Langerhans cell histiocytosis; 96% for germ cell tumours; 95% 
for renal tumours; 94% for lymphoma; 94% for retinoblasto-
ma; 85% for children with leukaemia; 83% for malignant bone 
tumours; 78% for neuroblastoma; 76% for hepatic tumours; 
75% for soft tissue sarcomas and 74% for central nervous sys-
tem neoplasms.
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Cancer incidence (2005 - 2014) in Switzerland, 
for children aged 0 - 14 years at diagnosis
Table 5 describes the tumours registered in the SCCR 
during the last ten years (2005-2014). Diagnoses are coded 
according to ICCC-3, most tumours were more common in 
boys than in girls.
The age- standardised incidence (according to the Euro-
pean standard population) of any childhood cancer (not in-
cluding Langerhans cell histiocytosis) was 16.1 per 100,000 
person- years. Incidence was highest among children aged 2 
years with 24.9 cases per 100,000 person- years (boys 28.0, 
girls 21.6). Incidence was lowest in 9 year olds with 8.6 cases 
per 100,000 person- years (boys 9.1, girls 8.0) (Figure 5 shows 
crude incidence rates in Swiss residents; age at diagnosis 0 - 14 
years; period of diagnosis 1995 - 2014; all diagnoses (ICCC - 3 
but not including Langerhans cell histiocytosis); Figure 6 shows 
age- and sex- specific incidence rates for age 0 - 14).
   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 648 33,6 1,6 4,8 5,4
 a. Lymphoid leukaemias 522 80,6 1,5 4,7 4,4
 b. Acute myeloid leukaemias 78 12,0 1,9 4,7 0,7
 c. Chronic myeloproliferative diseases 9 1,4 3,5 10,0 0,1
 d. Myelodysplastic syndrome and other myeloproliferative diseases 32 4,9 3,0 6,3 0,3
 e. Unspecified and other specified leukaemias 7 1,1 0,8 5,5 0,1
II Lymphomas and reticuloendothelial neoplasms 215 11,2 1,8 10,9 1,8
 a. Hodgkin lymphomas 96 44,7 0,9 12,7 0,8
 b. Non- Hodgkin lymphomas (except Burkitt lymphoma) 58 27,0 2,9 8,9 0,5
 c. Burkitt lymphoma 56 26,0 7,0 7,3 0,5
 d. Miscellaneous lymphoreticular neoplasms 5 2,3 0,3 1,3 0,0
 e. Unspecified lymphomas 0 NA NA NA NA
III CNS and miscellaneous intracranial and intraspinal neoplasms 442 22,9 1,2 6,8 3,7
 a. Ependymomas and choroid plexus tumour 48 10,9 1,3 2,7 0,4
 b. Astrocytomas 186 42,1 1,1 7,0 1,6
 c. Intracranial and intraspinal embryonal tumours 80 18,1 1,4 6,5 0,7
 d. Other gliomas 52 11,8 1,3 6,5 0,4
 e. Other specified intracranial and intraspinal neoplasms 67 15,2 1,2 10,8 0,6
 f. Unspecified intracranial and intraspinal neoplasms 9 2,0 0,8 8,6 0,1
IV Neuroblastoma and other peripheral nervous cell tumours 118 6,1 1,1 1,5 1,0
 a. Neuroblastoma and ganglioneuroblastoma 118 100,0 1,1 1,5 1,0
 b. Other peripheral nervous cell tumours 0 NA NA NA NA
V Retinoblastoma 42 2,2 0,8 1,0 0,4
VI Renal tumours 98 5,1 0,8 3,3 0,8
 a. Nephroblastoma and other nonepithelial renal tumours 93 94,9 0,8 3,2 0,8
 b. Renal carcinomas 5 5,1 0,7 12,8 0,0
 c. Unspecified malignant renal tumours 0 NA NA NA NA
VII Hepatic tumours 15 0,8 2,0 2,1 0,1
 a. Hepatoblastoma 14 93,3 1,8 1,9 0,1
 b. Hepatic carcinomas 1 6,7 0,0 14,1 0,0
 c. Unspecified malignant hepatic tumours 0 NA NA NA NA
Table 5 
Childhood cancer diagnosed in Switzerland 2005 - 2014: number of cases, relative frequency, sex ratio, median age at diagnosis and 
incidence standardised according to the  European standard population, by diagnostic groups according to ICCC - 3
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   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
VIII Malignant bone tumours 79 4,1 0,9 11,2 0,7
 a. Osteosarcomas 38 48,1 0,9 11,7 0,3
 b. Chondrosarcomas 1 1,3 0,0 14,4 0,0
 c. Ewing tumour and related sarcomas of bone 39 49,4 1,0 10,9 0,3
 d. Other specified malignant bone tumours 0 NA NA NA NA
 e. Unspecified malignant bone tumours 1 1,3 0,0 14,7 0,0
IX Soft tissue and other extraosseous sarcomas 139 7,2 1,4 7,8 1,2
 a. Rhabdomyosarcomas 78 56,1 1,4 5,5 0,7
 b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms 10 7,2 2,3 10,9 0,1
 c. Kaposi sarcoma 0 NA NA NA NA
 d. Other specified soft tissue sarcomas 40 28,8 0,9 11,1 0,3
 e. Unspecified soft tissue sarcomas 11 7,9 4,5 2,8 0,1
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 58 3,0 1,1 6,4 0,5
 a. Intracranial and intraspinal germ cell tumours 15 25,9 2,0 12,1 0,1
 b. Malignant extracranial and extragonadal germ cell tumours 18 31,0 0,6 0,2 0,2
 c. Malignant gonadal germ cell tumours 24 41,4 1,2 11,5 0,2
 d. Gonadal carcinomas 0 NA NA NA NA
 e. Other and unspecified malignant gonadal tumour 1 1,7 0,0 0,8 0,0
XI Other malignant epithelial neoplasms and malignant melanomas 71 3,7 0,6 12,2 0,6
 a. Adrenocortical carcinomas 2 2,8 1,0 6,4 0,0
 b. Thyroid carcinomas 14 19,7 0,3 13,5 0,1
 c. Nasopharyngeal carcinomas 2 2,8 1,0 13,6 0,0
 d. Malignant melanomas 15 21,1 0,5 10,4 0,1
 e. Skin carcinomas 7 9,9 1,3 7,0 0,1
 f. Other and unspecified carcinoma 31 43,7 0,6 12,0 0,3
XII Other and unspecified malignant neoplasms 3 0,2 2,0 0,0 0,0
 a. Other specified malignant tumours 2 66,7 1,0 1,8 0,0
 b. Other unspecified malignant tumours 1 33,3 0,0 0,0 0,0
Total (not including Langerhans cell histiocytosis) 1928 100,0 1,3 6,2 16,1
 Langerhans cell histiocytosis 59 3,0 1,4 5,2 0,5
Total (including Langerhans cell histiocytosis) 1987 100,0 1,3 6,2 16,6
 
* Incidence: newly diagnosed tumours in a one year time period per 100,000 persons (person - years) 
Swiss residents; age at diagnosis 0 - 14 years, period of diagnosis 2005 - 2014, all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 1987
Table 5 Continued
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Figure 6
Age-  and sex- specific incidence 
rates (per 100,000 person- years) in 
Switzerland for the last 10 years
Swiss residents; age at diagnosis 0 - 14 years; 
period of diagnosis 2005 - 2014; all diagnoses 
(ICCC - 3 but not including Langerhans 
cell histiocytosis); N = 1928
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Figure 5
Crude incidence rate (per 100,000 
person - years) in Switzerland, by sex 
and year of diagnosis for the last 
20 years (1995 - 2014)
Swiss residents; age at diagnosis 0 - 14 years; 
period of diagnosis 1995 - 2014; all diagnoses 
(ICCC - 3 but not including Langerhans cell 
histiocytosis); N = 3916
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3.4 Swiss residents aged 15 - 20 years 
 at diagnosis (N = 501)
Table 6 describes the tumours registered in the last ten 
years (2005 - 2014) diagnosed in adolescent patients (aged 
15 - 20 years at diagnosis, N = 501). Because data on adoles-
cents are currently not complete within the SCCR, we do not 
present incidence rates. In adolescents the sex ratio is closer to 
1 than in those aged 0 - 14 years at diagnosis. 
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases  61 12,2 1,4 16,4
 a. Lymphoid leukaemias  31 50,8 2,1 15,9
 b. Acute myeloid leukaemias  16 26,2 0,8 16,8
 c. Chronic myeloproliferative diseases  8 13,1 1,0 18,1
 d. Myelodysplastic syndrome and other myeloproliferative diseases  6 9,8 2,0 16,7
 e. Unspecified and other specified leukaemias  0 NA NA NA
II Lymphomas and reticuloendothelial neoplasms  131 26,3 0,8 16,7
 a. Hodgkin lymphomas  93 71,0 0,8 16,7
 b. Non - Hodgkin lymphomas (except Burkitt lymphoma)  32 24,4 1,0 17,0
 c. Burkitt lymphoma  5 3,8 1,5 17,9
 d. Miscellaneous lymphoreticular neoplasms  1 0,8 0,0 16,6
 e. Unspecified lymphomas  0 NA NA NA
III CNS and miscellaneous intracranial and intraspinal neoplasms  84 16,8 1,2 16,7
 a. Ependymomas and choroid plexus tumour  6 7,1 1,0 18,3
 b. Astrocytomas  26 31,0 0,7 16,7
 c. Intracranial and intraspinal embryonal tumours  16 19,0 1,7 16,5
 d. Other gliomas  10 11,9 1,0 16,8
 e. Other specified intracranial and intraspinal neoplasms  25 29,8 1,5 16,5
 f. Unspecified intracranial and intraspinal neoplasms  1 1,2 0,0 15,4
IV Neuroblastoma and other peripheral nervous cell tumours  0 NA NA NA
 a. Neuroblastoma and ganglioneuroblastoma  0 NA NA NA
 b. Other peripheral nervous cell tumours  0 NA NA NA
V Retinoblastoma  0 NA NA NA
VI Renal tumours  7 1,4 2,5 16,6
 a. Nephroblastoma and other nonepithelial renal tumours  2 28,6 0,0 16,0
 b. Renal carcinomas  5 71,4 1,5 17,4
 c. Unspecified malignant renal tumours  0 NA NA NA
VII Hepatic tumours  2 0,4 0,0 17,4
 a. Hepatoblastoma  0 NA NA NA
 b. Hepatic carcinomas  2 100,0 0,0 17,4
 c. Unspecified malignant hepatic tumours  0 NA NA NA
VIII Malignant bone tumours  48 9,6 1,5 16,2
 a. Osteosarcomas  33 68,8 1,8 16,3
 b. Chondrosarcomas  1 2,1 0,0 15,1
 c. Ewing tumour and related sarcomas of bone  12 25,0 1,0 16,0
 d. Other specified malignant bone tumours  2 4,2 1,0 16,7
 e. Unspecified malignant bone tumours  0 NA NA NA
Table 6 
Adolescent cancer diagnosed in Switzerland 2005 - 2014: number of cases, relative frequency, sex ratio, median age at diagnosis  
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Table 6 Continued
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
IX Soft tissue and other extraosseous sarcomas  33 6,6 0,9 16,7
 a. Rhabdomyosarcomas  13 39,4 0,9 16,1
 b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms  3 9,1 0,0 15,8
 c. Kaposi sarcoma  0 NA NA NA
 d. Other specified soft tissue sarcomas  13 39,4 0,4 17,4
 e. Unspecified soft tissue sarcomas  4 12,1 3,0 16,8
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads  38 7,6 8,5 17,8
 a. Intracranial and intraspinal germ cell tumours  3 7,9 0,0 17,2
 b. Malignant extracranial and extragonadal germ cell tumours  0 NA NA NA
 c. Malignant gonadal germ cell tumours  33 86,8 15,5 18,0
 d. Gonadal carcinomas  2 5,3 0,0 15,7
 e. Other and unspecified malignant gonadal tumour  0 0,0 NA NA
XI Other malignant epithelial neoplasms and malignant melanomas  93 18,6 0,7 18,1
 a. Adrenocortical carcinomas  1 1,1 0,0 17,0
 b. Thyroid carcinomas  25 26,9 0,1 18,0
 c. Nasopharyngeal carcinomas  3 3,2 2,0 18,7
 d. Malignant melanomas  29 31,2 0,9 18,6
 e. Skin carcinomas  9 9,7 0,8 18,4
 f. Other and unspecified carcinoma  26 28,0 1,4 17,7
XII Other and unspecified malignant neoplasms  2 0,4 0,0 16,3
 a. Other specified malignant tumours  2 100,0 0,0 16,3
 b. Other unspecified malignant tumours  0 NA NA NA
  Total (not including Langerhans cell histiocytosis)  499 100,0 1,1 16,8
 Langerhans cell histiocytosis  2 0,4 1,0 16,4
  Total (including Langerhans cell histiocytosis)  501 100,0 1,1 16,8
Age at diagnosis 15 - 20 years, period of diagnosis 2005 - 2014, all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); N = 501
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4. Research on childhood cancer
The research of the childhood cancer registry focusses on 
three main topics: Aetiology of childhood cancer, long- term 
outcomes, and follow - up care after childhood cancer or young 
adult cancer. These topics are described with their background, 
aims, methods, recent findings, ongoing studies, and contacts 
in the remainder of Chapter 4. Additional information is avail-
able from the investigators and our website (www.childhood-
cancerregistry.ch). Further, we thank the supporters for their 
generous contributions towards the research projects.
All ongoing studies, their funding sources and the senior 
investigator are summarized in Table 7.
Table 7
Research grants of the SCCR, summary
No Project name Senior investigator Funding sources Study period   
Aetiology of childhood cancer
1 Spatial and spatio - temporal clustering of childhood   Spycher BD Swiss Cancer Research 01.2014 - 12.2016
 cancer: The role of infections and environmental hazards   (KFS - 3515 - 08 - 2014)  
2 The spatial epidemiology of childhood cancer in Switzerland Spycher BD Swiss National Science  09.2013 - 08.2016
   Foundation (PZ00P3_147987) 
3 The role of population mixing and exposure to infections in  Spycher BD Swiss Cancer Research 01.2013 - 12.2014
 the aetiology of childhood leukaemia: A national cohort study  (KFS - 3049 - 08 - 2012) 
4 Childhood cancer and geographically defined exposures  Spycher BD Federal Office of Public Health 03.2013 - 11.2013
 in Switzerland: A census - based nationwide cohort study  (12.008357) 
5 Childhood cancer and vicinity of residence to petrol stations Kuehni CE Federal Office of Public Health 06.2010 - 02.2013
  and roads: A census - based nationwide cohort study (PETROL)  (10.002946) 
6 Childhood cancer and nuclear power plants in Switzerland:  Kuehni CE Swiss Cancer League 09.2008 - 02.2011
 A census - based cohort study  (02224 - 03 - 2008); 
   Federal Office of Public Health
   (08.001616) 
Outcome research (Long - term outcomes, follow - up care, international collaboration)
1 Swiss Childhood Cancer Survivor Study (SCCSS) Kuehni CE, Angst R Cancer League Aarau 01.2012 - 12.2012
  Kuehni CE,  Cancer League Zurich  08.2010 - 07.2011
  Bergstraesser E
  Kuehni CE Cancer League Bern  04.2009 - 03.2010
  Von der Weid NX,  Swiss Cancer League  07.2008 - 06.2010
  Kuehni CE (KLS - 2215 - 02 - 2008)   
  Von der Weid NX,   Swiss Cancer League  01.2006 - 10.2008
  Kuehni CE (KLS - 1605 - 10 - 2004)   
  Kuehni CE Kinderkrebshilfe Schweiz  since 2006
2 PanCare Studies in Fertility and Ototoxicity to improve Kuehni CE Swiss Cancer League 07.2014 - 06.2017
 Quality of Life after Cancer during Childhood,   (KLS - 3412 - 02 - 2014)
 Adolescence and Young Adulthood (PanCareLIFE) Kuehni CE EU (FP7 - HEALTH - F2 - 2013 - 11.2013 - 10.2018
   602030; project no. 602030) 
3 Dietary habits, nutrition and risk of late effects  Bochud M, Kuehni CE Swiss Cancer League 07.2015 - 06.2018
 after childhood cancer   (KLS - 3644 - 02 - 2015) 
4 Psychological late effects in long - term childhood cancer  Michel G Krebsliga Zentralschweiz 11.2015 - 10.2017
 survivors – Development of guidelines for follow - up care 
5 PanCare childhood and adolescent cancer survivor care  Kuehni CE Swiss Cancer Research 08.2011 - 07.2014
 and follow - up studies (PanCareSurFup)  (KFS - 02783 - 02 - 2011)   
  Kuehni CE EU (FP7 - HEALTH - F2 - 2010 - 02.2011 - 01.2017
   257505; project no. 257505) 
6 Mortality after cancer in childhood and adolescence  Kuehni CE Swiss National Science  08.2012 - 08.2015
   Foundation (PDFMP3_141775) 
  Kuehni CE Swiss Bridge 
7 Follow - up care after childhood and young adult  Michel G Swiss National Science 08.2009 - 08.2014
 cancer (CCFU)  Foundation (PZ00P3_121682
     and PZ00P3_141722)   
8 Effectiveness of transition from paediatric to adult  Michel G Swiss Cancer League 04.2011 - 04.2014
 care after childhood cancer  (KFS - 02631 - 08 - 2010) 
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No Project name (continued) Senior investigator Funding sources Study period   
9 Parents of long-term childhood cancer survivors Michel G Swiss National Science   since 2013
   Foundation 
   (100019_153268 /1)
   Kinderkrebshilfe Schweiz 
10 Fertility after Chemo- and Radiotherapy in Childhood Michel G Kinderkrebshilfe Schweiz  since 2012
 and Adolescence, FeCt – Multicentre  
11 Risk of cancer and long-term mortality in children  Mullis P, Kuehni CE Swiss Cancer League 07.2012-12.2013
 treated with growth hormone:    (KLS-2948-02-2012)
 Swiss participation in the EU FP7 project (SAGhE) Mullis P EU (FP-HEALTH-F2-2009- 04.2011-03.2014
   223497)   
  Mullis P, Kuehni CE Swiss Cancer League  07.2010-12.2012 
   (KLS-02586-02-2010)   
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4.1 Aetiology of childhood cancer
 Background
The aetiology of childhood cancers remains largely un-
known. For leukaemia, the most frequent childhood cancer, 
known risk factors include trisomy 21, certain rare genetic 
syndromes, some common germline genetic variants, high 
birthweight, and high parental age at birth. Regarding envi-
ronmental exposures, only ionising radiation at medium to 
high doses is an established risk factor – both for leukaemia 
and CNS tumours. Numerous other environmental factors are 
being discussed as potential risk factors. These include: low 
dose ionising radiation (e.g. natural background radiation and 
diagnostic radiation), traffic related air pollution, electromag-
netic fields (e.g. from power lines, radio and TV transmitters, 
or mobile phones) pesticides, and infections.
 Aims
The broad aims of the research group are to investigate 
whether: 
• Cancer risks in children are associated with environmen-
tal exposures, such as ionising and non- ionising radia-
tion, air pollution and exposure to infectious diseases, as 
well as parents workplace exposures;
• Cancer risks in children are associated with socio eco-
nomic, family or perinatal exposures;
• Cases of cancer tend to cluster in space and /or in space 
and time and, if yes, to elicit aetiological clues from the 
pattern of clustering.
 Methods
Clinical and residential information on diagnosed cases 
are obtained from the SCCR. Data on the population at risk 
are obtained from the Swiss National Cohort (SNC) which 
includes the entire Swiss resident population at census time 
points (1990, 2000, and annually from 2010 onward). Record 
linkage between the two datasets allows investigating cancer 
incidence on a nationwide scale with a cohort design. The 
SCCR collects geocoded address histories from birth to diag-
nosis allowing to distinguish different exposure time windows. 
Geocoded places of residence are also available for the entire 
population from the SNC. This allows calculating geographical-
ly determined exposures such as distance to highways or NO
2
 
concentration levels (based on spatial pollution models) for the 
entire population at risk. The SNC also provides demographic, 
socioeconomic and perinatal data for the entire population. 
The availability of precise geocodes of residence allows assess-
ing spatial and spatio- temporal clustering using methods for 
point pattern data rather than methods for less precise region-
al count data (e.g. aggregated at municipality level).
 Current status
A, Recent findings: A summary of our recent research 
and findings is given in [Lupatsch - 2016a]. We found evi-
dence of increased risks of childhood leukaemia and CNS 
tumours among children exposed to higher levels of natural 
background radiation (terrestrial gamma and cosmic radia-
tion) [Spycher - 2015a, 2015b, 2015c]. Young children living 
in the immediate proximity (<100m) of highways were found 
to have an increased leukaemia risk [Spycher - 2015d]. We 
found little evidence of associations between childhood leu-
kaemia and commonly used measures of population mixing 
[Lupatsch - 2015b, c] or for associations between leukaemia 
risk and socioeconomic status [Adam - 2015]. However, we did 
find evidence of a temporal association between childhood 
leukaemia and periods of rapid population growth in Swiss 
municipalities [Lupatsch - 2016d]. We found evidence for spa-
tio- temporal clustering of leukaemia around the time of birth, 
but not around the time of diagnosis [Kreis - 2016].
B, Ongoing studies: In ongoing studies we are investigat-
ing whether: i) Childhood cancer is associated with increased 
air concentrations of benzene and NO
2
; ii) Childhood leukae-
mia is associated with perinatal characteristics (including pa-
rental age, birth order, age difference to next older sibling, and 
birth weight); iii) Cases of childhood leukaemia born close in 
time and space to another case (clustered cases) differ from 
non- clustered cases with respect to diagnostic, socio economic 
characteristics and environmental exposures; and iv) whether 
there is evidence for spatial clustering in Switzerland. Further-
more, we are v) collaborating in an international case control 
study on the association between childhood cancer and prox-
imity to power lines.
 Contact
The research team consists of Ben Spycher, Claudia Kuehni, 
Christian Kreis and Garyfallos Konstantinoudis.
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4.2 Long- term outcomes
 Background
Cancer is the most common disease- related cause of death 
during childhood in the Western world. Thanks to therapeutic 
improvements in the recent decades, survival rates for childhood 
cancer now exceed 80%, leading to a growing population of 
long- term survivors. However, cancer and its treatment can 
cause adverse late effects, such as second primary malignan-
cies, cardiovascular disease, hearing loss and infertility. These 
adverse late effects may affect survivors’ health, health be-
haviour and quality of life, and may lead to premature death. 
Comprehensive data on the burden of late effects of childhood 
cancer including premature mortality and their risk factors are 
scarce. The SCCR has a broad research program focusing on 
long- term outcomes that includes the national Swiss Child-
hood Cancer Survivor Study (SCCSS) and a study on cause- spe-
cific long- term mortality. 
 Aims 
The research group aims: 
• To investigate prevalence, incidence and spectrum of 
somatic and psychosocial outcomes including second 
primary neoplasms, somatic health, mental health, 
  educational and social outcomes, health- related quality 
of life, and cause- specific long- term mortality.
• To determine sociodemographic, cancer- and treatment 
related predictors associated with long- term outcomes.
• To describe health behaviours in long- term survivors.
 Methods
This prospective cohort study is based on children and ad-
olescents registered in the SCCR. 
Study population: All individuals who are at least 5-year sur-
vivors, who were diagnosed with cancer at age < 21 years, and 
were Swiss residents at time of diagnosis are eligible. 
Collected data: A detailed questionnaire is sent to child-
hood cancer survivors and their parents to obtain data about 
somatic, psychosocial, and mental health outcomes. For com-
parison, a similar questionnaire is sent to siblings of survivors. 
Questionnaire data are complemented with phone interviews 
to patients and are validated with information from general 
practitioners and hospital records, e.g. audiometric or lung 
function tests to validate hearing problems or lung diseases. 
Furthermore, we collect data from municipal population reg-
istries to obtain vital statistics including dates of death, and 
Swiss mortality statistics to obtain causes of death. For some 
studies, we also collect saliva samples for genetic analyses. 
These broad data make it possible to investigate prevalence 
and incidence of adverse late effects and to identify their pre-
dictors in Swiss survivors.
Response rate: For the SCCSS questionnaire survey, we 
contacted 2930 five- years survivors aged 0 to 16 years at diag-
nosis, 2235 (76%) completed our questionnaire. Among 598 
contacted survivors aged 16 - 20 years at diagnosis whom we 
contacted, 320 (57%) participated. We also contacted 1522 
siblings, of whom 866 (57%) participated.
 Current status
A, Recent findings
This study offers the first national-level data on adverse 
late effects, health behaviour, survival and long- term mortality 
after cancer in childhood and adolescence in Switzerland. The 
study is ongoing and we are currently contacting new 5 - year 
survivors diagnosed between 2005 - 2010. We obtained causes 
of death of 3965 of the 5 - year survivors who subsequently 
died. We analyse and publish our findings continuously. Previ-
ous publications have included topics like health-related quali-
ty of life, education, cognitive problems, partnership, income, 
physical activity, nutrition, survival, and mortality. Our findings 
will help to identify patients who are at increased risk for late 
effects, to adjust therapies and to develop tailored follow- up 
programs for survivors.
Health- related quality of life (HRQoL): We found that the 
overall HRQoL of young survivors (8 - 16 years) was comparable 
to population norms for most parent- reported dimensions and 
higher for most self- reported dimensions [Wengenroth - 2015]. 
However, older survivors (>16 years) had lower HRQoL than 
their siblings, and among survivors, those with chronic health 
problems had the lowest health- related quality of life [Rueegg-
 2013]. Survivors of acute lymphoblastic leukemia reported 
good HRQoL, even after a relapse [Essig - 2012].
Educational and social outcomes: We also showed that 
survivors achieved educational levels similar to the general 
population [Kuehni - 2012]. Survivors younger than 20 years 
were more likely than their siblings to report cognitive prob-
lems [Wengenroth - 2015]. We found lower personal income 
in survivors than in siblings [Wengenroth - 2016]. However, sur-
vivors’ personal income may increase later because treatment 
can push back education and carreer training and cause sur-
vivors to start working later than their peers. Survivors are less 
likely than peers to be married or in a life partnership [Wen-
genroth - 2014]. This might be because survivors take longer to 
reach their final educational achievement, which might in turn 
encourage them to delay marriage.
Physical activity: We found that daily physical activity 
and sport levels in survivors were similar to the general pop-
ulation. Physical activity was mainly determined by socio- de-
mographic and cultural factors [Rueegg - 2012a]. However, 
we found that survivors are at high risk of suffering from per-
formance limitations in sports and in daily living activities and 
that these limitations differed strongly between diagnostic 
groups [Rueegg - 2012b]. Despite these physical performance 
limitations, many survivors maintained healthy activity levels 
[Rueegg -2013].
Nutrition: We showed that the adherence to dietary rec-
ommendations among survivors was similar to their siblings 
and the general population, but poor overall [Belle - submitted]. 
Hearing loss: We found that the burden of hearing loss 
as a late effect after ototoxic cancer treatment has stabilized in 
recently treated survivors, which suggests that survivors have 
benefited from new treatment regimens that use less ototoxic 
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radiation and more carefully dosed platinum compounds [Weiss 
- accepted].
Mortality: We found that the mortality of five- year survi-
vors of childhood cancers is elevated compared to the general 
population, with recurrence and progression of the original 
cancer as the most common causes of death up to 24 years 
after diagnosis [Schindler - 2016].
 B, Ongoing studies 
Ongoing studies focus on different somatic health prob-
lems and health behaviours:
i) diseases; ii) cardiac diseases; iii) hearing loss; and iv) di-
etary habits and excess weight. We are also collaborating with 
international studies (see International collaborations).
 Contact
The research team consists of Claudia Kuehni, Fabiën Belle, 
Rahel Kasteler, Rahel Kuonen, Matthias Schindler, Grit Sommer, 
Annette Weiss, Gisela Michel and Nicolas von der Weid.
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4.3 International collaborations 
 Background
Late effects of childhood cancer and its treatment are 
common, but numbers in individual countries are low. There-
fore, pooling of data into large international cohorts is essen-
tial to identify risk factors for late effects using observational 
data and genetic tools. Survivors can benefit from personal-
ized, evidence- based care based on their individual risk; and 
future patients may benefit from adapted treatment, that 
cause less severe side effects. 
International studies on childhood cancer often also in-
clude systematic reviews that summarize the evidence on risk 
factors of late effects. These provide the basis for creating new 
guidelines for the clinical long- term follow- up of survivors of 
cancer diagnosed at a young age.
The SCCR collaborates with other childhood cancer co-
horts [Bhatia - 2015, Winther - 2015], participates in European 
studies to investigate late effects, and is involved in the devel-
opment of international guidelines for clinical long- term fol-
low- up of childhood and adolescent cancer survivors.
 Aims
Within the international collaborations, we aim to inves-
tigate:
• Prevalence and incidence of late effects of childhood and 
adolescent cancer and its treatment
• Risk factors for these late effects
We also aim to develop guidelines to improve the health 
and quality of life of current and future survivors of childhood 
cancer.
 Methods
Swiss patients of childhood and adolescence cancer are 
part of a Pan- European cohort. Researchers within this Euro-
pean collaboration can then select patients with late effects, 
for example patients with a second primary cancer, cardiac or 
hearing problems, for nested case- control or case- cohort stud-
ies. Within these studies, researchers can identify non- genetic 
and genetic risk factors of late effects.
Experts and the International Guideline Harmonization 
Group (IGHG, http: / /www.ighg.org /) write up systematic re-
views to develop evidence- based, standardised guidelines for 
clinical follow- up of survivors.
 Current status
A, Ongoing studies:
Swiss patients of childhood and adolescence cancer are 
part of Pan- European cohorts. Researchers within this Euro-
pean collaboration can then select patients with late effects, 
for example patients with a second primary cancer, cardiac or 
hearing problems, for nested case- control or case- cohort stud-
ies. Within these studies, researchers can identify non- genetic 
and genetic risk factors of late effects. Currently, we are collab-
orating in two ongoing studies:
PanCareSurFup (PanCare childhood and adolescent can-
cer survivor care and follow- up studies; http: / /www.pancar-
esurfup.eu /) 
This project investigates the burden and risk factors of 
the most severe and life threatening late effects, namely sec-
ond primary neoplasms, cardiovascular disease and premature 
death. We contributed with 4719 Swiss 5 - year survivors to the 
Pan- European cohort and with detailed treatment data from 
medical records of 139 Swiss survivors to the European nested-
 case control studies. 
Recent findings: A new method to facilitate valid and 
consistent grading of cardiac events in childhood cancer survi-
vors has been published [Feijen - 2014] and several other publi-
cations are in preparation.
PanCareLIFE (PanCare Studies in Fertility and Ototoxicity 
to Improve Quality of Life after Cancer during Childhood, Ad-
olescence and Young Adulthood; http: / /www.pancarelife.eu /) 
This project investigates hearing loss, infertility and quality 
of life. We identified survivors at risk for hearing loss and col-
lected their audiograms. We will contribute questionnaire data 
on hearing loss, fertility and quality of life from the SCCSS. We 
will be responsible, together with the University of Münster in 
Germany, for the statistical analysis of quality of life data from 
eight European countries.
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B, Development of guidelines
In close collaboration with European and American ex-
perts and the International Guideline Harmonization Group 
(IGHG, http: / /www.ighg.org /), we write systematic reviews 
do develop evidence- based, standardized guidelines for clin-
ical follow- up of survivors. We are currently involved as chairs, 
work group (WG) leaders and group members in the develop-
ment of the following guidelines: 
l Hearing loss (ototoxicity)
 • Chairs: Wendy Landier (USA), Richard Cohn (AUS)
 • WG leaders: Claudia Kuehni (CH), Thorsten Langer (DE)
l Pulmonary dysfunction
 • Chairs and WG leaders: Claudia Kuehni (CH), 
   Andrew Dietz (USA)
l Fatigue, mental health and psychosocial problems
 • Chairs: Gisela Michel (CH), 
   Jordan Gilleland Marchak (USA)
 • Fatigue WG leaders: Kathrin Scheinemann (CH),   
 Gisela Michel (CH)
 • Mental Health WG leaders: Janine Vetsch (CH),  
   Jordan Gilleland Marchak (USA)
Once the guidelines will be available, all centres of the 
Swiss Paediatric Oncology Group will implement these guide-
lines in Switzerland.
Recent findings: A survey among paediatric oncolo-
gy /haematology clinics from 44 European countries found 
that many clinics have insufficient or lack programmes for 
long- term follow- up into adulthood for survivors of childhood 
cancer [Brown - 2015]. This study showed that available guide-
lines are not universally used throughout Europe and we need 
to further develop and disseminate Pan- European long- term 
follow- up guidelines.
 Contact
The research team consists of Claudia Kuehni, Rahel Kas-
teler, Rahel Kuonen, Grit Sommer, Annette Weiss, Gisela Michel 
and Nicolas von der Weid.
30
4.4 Psychosocial outcomes and follow-up care
 Background
Treatment for cancer in children and young adults has 
greatly improved and most patients can be cured today. How-
ever, more than 50% of survivors of childhood cancer suffer 
from late effects. Similarly, parents might suffer long after their 
child has been cured. To detect and treat late effects as early as 
possible, most survivors should continue to attend follow- up 
care long after their cancer has been cured. Follow- up care 
needs to be constantly updated to meet the current status of 
research. International guidelines summarising the care need-
ed after different cancers and treatment are necessary. Ad-
ditionally, while various models of follow- up care have been 
described, so far none has been implemented in Switzerland. 
A successful model must not only take clinical aspect into ac-
count but also survivors’ preferences and needs.
 Aims
The research group aims to:
• Describe follow- up care models available across Europe, 
and preferences for a follow- up model among Swiss 
childhood and young adult cancer survivors, parents and 
physicians (oncologists and general practitioners)
• Evaluate the transition / transfer from paediatric to adult 
care in survivors of childhood cancer
• Describe psychological and socio- demographic out-
comes, as well as needs in parents of long- term child-
hood cancer survivors
 Methods
To describe follow- up care models in Europe, we invited 
198 clinics and follow- up programmes in Europe to complete 
a questionnaire survey describing the follow- up care available 
at their institution. To assess preferences for different models 
of follow- up care, a questionnaire survey assessed opinions 
and perspectives on both currently used and desired opti-
mal follow- up care among survivors, parents, paediatric and 
adult oncologists  / haematologists and family practitioners. 
We evaluated the transition from paediatric to adults among 
childhood cancer survivors using medical records. Finally, we 
will contact parents in a questionnaire survey to assess posi-
tive and negative psychological, familial, and social outcomes 
[Mader - 2016]. These outcomes will be compared to the Swiss 
general population.
 Current status
A, Recent Findings: 
Follow- up care: Our survey among European paediatric 
oncology /haematology clinics found that many still lacked pro-
grammes for long- term follow- up into adulthood [Essig - 2012, 
Brown - 2015]. Additionally, a large proportion of Swiss sur-
vivors do not attend regular follow- up care [Michel - 2011, 
Rebholz - 2011, Lupatsch - 2016e]. Survivors and their parents 
desire precise information on late effects and follow- up care 
[Gianinazzi - 2014a, Vetsch - 2015]. Most survivors and par-
ents reported preferences for care by a specialist (oncologist) 
[Vetsch - 2016, Christen - 2016].
Psychological late effects: We found that survivors are at in-
creased risk for psychological distress [Michel - 2010, Gianinazzi -
 2013, Gianinazzi - 2014b, Michel - 2015, Gianinazzi - 2016] or 
other negative psychosocial outcomes [Wengenroth - 2014, 
2015a, 2015b, Kuehni - 2012a, Rebholz - 2012].
Transition: In Switzerland, there is no specialised transi-
tion programme for survivors of childhood cancer from pae-
diatric to adult care. We investigated if patients are receiving 
e.g. follow- up information after release from the paediatric 
oncology clinic [Gianinazzi - 2015]. Patient- adapted informa-
tion on diagnosis, treatment and future follow- up, provided at 
the time of discharge, was rarely found. 
 B, Ongoing studies: 
The study on parents of childhood cancer survivors will be 
the first population- based study among parents of long- term 
survivors of childhood cancer and will shed light on their psy-
chological well- being, social outcomes and the needs they 
have for their children and themselves.
 Contact
The research team consists of Gisela Michel, Katharina 
Roser, Luzius Mader, Julia Bänziger, Janine Vetsch, Salome 
Christen, Claudia Kuehni, and Nicolas von der Weid.
31Swiss Childhood Cancer Registry Annual Report  2014/2015  Publications
All articles published using SCCR data from January 2007 
– June 2016  are reported below. Additional publications relat-
ed to the SCCR or SPOG can be found on the SCCR and SPOG 
websites: www.childhoodcancerregistry.ch and www.spog.ch.
5.1 Original articles (Peer reviewed journals) 
 2016
 1. Adam M, Rueegg CS, Schmidlin K, Spoerri A, Niggli F, Grotzer 
M, von der Weid NX, Egger M, Probst - Hensch N, Zwahlen 
M, Kuehni CE. Socioeconomic disparities in childhood cancer 
survival in Switzerland. Int J Cancer. 2016; 138(12):2856 - 66.
 2. Christen S, Vetsch J, Mader L, Dehler S, Korol D, Kuehni CE, 
Rueegg CS, Michel G. Preferences for the organization of 
long - term follow - up in adolescent and young adult cancer 
survivors. Support Care Cancer. 2016; 24(8):3425 - 36.
 3. Essig S, Steiner C, Kuehni CE, Weber H, Kiss A. Improving 
Communication in Adolescent Cancer Care: A Multiperspec-
tive Study. Pediatr Blood Cancer. 2016; 63(8):1423 - 30.
 4. Gianinazzi ME, Rueegg CS, Vetsch J, Luer S, Kuehni CE, Mi-
chel G, Swiss Pediatric Oncology G. Cancer’s positive flip 
side: posttraumatic growth after childhood cancer. Support 
Care Cancer. 2016; 24(1):195 - 203.
 5. Kreis C, Grotzer M, Hengartner H, Daniel Spycher B, Swiss 
Paediatric Oncology G, the Swiss National Cohort Study G. 
Space - time clustering of childhood cancers in Switzerland: A 
nationwide study. Int J Cancer. 2016; 138(9):2127 - 35.
 6. Lupatsch JE, Kreis C, Zwahlen M, Niggli F, Ammann RA, 
Kuehni CE, Spycher BD, Swiss Paediatric Oncology G, Swiss 
National Cohort Study G. Temporal association between 
childhood leukaemia and population growth in Swiss munic-
ipalities. Eur J Epidemiol. 2016d.
 7. Lupatsch JE, Wengenroth L, Rueegg CS, Teuffel O, 
Gumy - Pause F, Kuehni CE, Michel G, Swiss Paediatric Oncol-
ogy G. Follow - Up Care of Adolescent Survivors of Childhood 
Cancer: The Role of Health Beliefs. Pediatr Blood Cancer. 
2016e; 63(2):318 - 25.
 8. Mader L, Rueegg CS, Vetsch J, Rischewski J, Ansari M, Kueh-
ni CE, Michel G, Swiss Paediatric Oncology G. Employment 
Situation of Parents of Long - Term Childhood Cancer Survi-
vors. Plos ONE. 2016; 11(3):e0151966.
 9. Mulder RL, van der Pal HJ, Levitt GA, Skinner R, Kremer 
LC, Brown MC, Bardi E, Windsor R, Michel G, Frey E. Tran-
sition guidelines: An important step in the future care for 
childhood cancer survivors. A comprehensive definition as 
groundwork. Eur J Cancer. 2016; 54:64 - 8.
 10. Schindler M, Spycher BD, Ammann RA, Ansari M, Michel 
G, Kuehni CE, Swiss Paediatric Oncology G, Swiss Paediatric 
Oncology Group S. Cause - Specific Long - Term Mortality in 
Survivors of Childhood Cancer in Switzerland: A Population 
Based Study. Int J Cancer. 2016; 139(2):322 - 33.
11. Vetsch J, Rueegg CS, Mader L, Bergstraesser E, Rischews-
ki J, Kuehni CE, Michel G, Swiss Paediatric Oncology G. 
Follow - up care of young childhood cancer survivors: at-
tendance and parental involvement. Support Care Cancer. 
2016; 24(7):3127 - 38.
12. Vienneau D, Infanger D, Feychting M, Schuz J, Schmidt LS, 
Poulsen AH, Tettamanti G, Klaeboe L, Kuehni CE, Tynes T, Von 
der Weid N, Lannering B, Roosli M. A multinational case - con-
trol study on childhood brain tumours, anthropogenic fac-
tors, birth characteristics and prenatal exposures: A valida-
tion of interview data. Cancer Epidemiol. 2016; 40:52 - 59.
13. Wengenroth L, Sommer G, Schindler M, Spycher BD, von der 
Weid NX, Stutz - Grunder E, Michel G, Kuehni CE, Swiss Pae-
diatric Oncology G. Income in Adult Survivors of Childhood 
Cancer. Plos ONE. 2016; 11(5):e0155546.
 2015
14. Adam M, Kuehni CE, Spoerri A, Schmidlin K, Gumy - Pause 
F, Brazzola P, Probst - Hensch N, Zwahlen M. Socioeconomic 
  Status and Childhood Leukemia Incidence in Switzerland. 
Front Oncol. 2015; 5:139.
15. Adel Fahmideh M, Lavebratt C, Schuz J, Roosli M, Tynes T, 
Grotzer MA, Johansen C, Kuehni CE, Lannering B, Prochazka 
M, Schmidt LS, Feychting M. CCDC26, CDKN2BAS, RTEL1, 
and TERT Polymorphisms in Pediatric Brain Tumor Suscepti-
bility. Carcinogenesis. 2015; 36(8):876 - 82.
16. Brown MC, Levitt GA, Frey E, Bardi E, Haupt R, Hjorth L, 
Kremer L, Kuehni CE, Lettner C, Mulder RL, Michel G, Skin-
ner R, on behalf of the PanCareSurFup C. The views of Eu-
ropean clinicians on guidelines for long - term follow - up of 
childhood cancer survivors. Pediatr Blood Cancer. 2015; 
62:322 - 328.
17. Gianinazzi ME, Rueegg CS, Zimmerman K, Kuehni CE, Michel 
G, Swiss Paediatric Oncology G. Intra - Rater and Inter - Rater 
Reliability of a Medical Record Abstraction Study on Tran-
sition of Care after Childhood Cancer. Plos ONE. 2015; 
10(5):e0124290.
18. Hjorth L, Haupt R, Skinner R, Grabow D, Byrne J, Karner S, 
Levitt G, Michel G, van der Pal H, Bárdi E, Beck J, de Vathaire 
F, Essig S, Frey E, Garwicz S, Hawkins M, Jakab Z, Jankovic 
M, Kazanowska B, Kepak T, Kremer L, Lackner H, Sugden E, 
Terenziani M, Zadravec Zaletel L, Kaatsch P on behalf of the 
PanCare Network. Survivorship after childhood cancer: Pan-
Care: A European network to promote optimal long‐term 
care. European Journal of Cancer.2015; 51(19), 1203–1211.
19. Lupatsch JE, Kuehni CE, Niggli F, Ammann RA, Egger M, Spy-
cher BD. Population mixing and the risk of childhood leu-
kaemia in Switzerland: a census - based cohort study. Eur J 
Epidemiol. 2015b; 30(12):1287 - 98.
20. Magi T, Kuehni CE, Torchetti L, Wengenroth L, Luer S, 
Frei - Erb M. Use of Complementary and Alternative Medicine 
in Children with Cancer: A Study at a Swiss University Hospi-
tal. Plos ONE. 2015; 10(12):e0145787.
21. Michel G, Vetsch J. Screening for psychological late effects 
in childhood, adolescent and young adult cancer survivors: a 
systematic review. Current Opinion in Oncology. 2015; 7(4), 
297 - 305.
22. Schindler M, Mitter V, Bergstraesser E, Gumy - Pause F, Mi-
chel G, Kuehni CE. Death certificate notifications in the Swiss 
Childhood Cancer Registry: assessing completeness and reg-
istration procedures. Swiss Med Wkly. 2015; 145:w14225.
5. Publications of the Swiss Childhood Cancer Registry
32
23. Spycher BD, Feller M, Roosli M, Ammann RA, Diezi M, Egger 
M, Kuehni CE. Childhood cancer and residential exposure 
to highways: a nationwide cohort study. Eur J Epidemiol. 
2015d; 30(12):1263 - 75.
24. Spycher BD, Lupatsch JE, Zwahlen M, Roosli M, Niggli F, 
Grotzer MA, Rischewski J, Egger M, Kuehni CE, Swiss Pediat-
ric Oncology G, Swiss National Cohort Study G. Background 
ionizing radiation and the risk of childhood cancer: a cen-
sus - based nationwide cohort study. Environ Health Perspect. 
2015a; 123(6):622 - 8.
25. Swerdlow AJ, Cooke R, Albertsson - Wikland K, Borgstrom B, 
Butler G, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse 
E, Gausche R, Giacomozzi C, Kiess W, Hokken - Koelega AC, 
Kuehni CE, Landier F, Maes M, Mullis PE, Pfaffle R, Savendahl 
L, Sommer G, Thomas M, Tollerfield S, Zandwijken GR, Car-
el JC. Description of the SAGhE Cohort: A Large European 
Study of Mortality and Cancer Incidence Risks after Child-
hood Treatment with Recombinant Growth Hormone. Horm 
Res Paediatr. 2015; 84(3):172 - 83.
26. Vetsch J, Rueegg CS, Gianinazzi ME, von der Weid NX, Mi-
chel G. Information provision and information needs in par-
ents of long - term childhood cancer survivors. Pediatr Blood 
& Cancer. 2015; 62 (5), 859 - 866.
27. Wengenroth L, Gianinazzi ME, Rueegg CS, Luer S, Berg-
straesser E, Kuehni CE, Michel G. Health - related quality of 
life in young survivors of childhood cancer. Qual Life Res. 
2015a; 24(9):2151 - 61.
28. Wengenroth L, Rueegg CS, Michel G, Gianinazzi ME, Essig 
S, von der Weid NX, Grotzer M, Kuehni CE, Swiss Paediat-
ric Oncology Group S. Concentration, working speed and 
memory: Cognitive problems in young childhood cancer 
survivors and their siblings. Pediatr Blood Cancer. 2015b; 
62(5):875 - 82.
 2014
29. Essig S, Li Q, Chen Y, Hitzler J, Leisenring W, Greenberg M, 
Sklar C, Hudson MM, Armstrong GT, Krull KR, Neglia JP, 
Oeffinger KC, Robison LL, Kuehni CE, Yasui Y, Nathan PC. 
Risk of late effects of treatment in children newly diagnosed 
with standard - risk acute lymphoblastic leukaemia: a report 
from the Childhood Cancer Survivor Study cohort. Lancet 
Oncol. 2014; 15(8):841 - 51.
30. Feijen EL, van der Pal HJ, van Dalen EC, Mulder RL, Bardi E, 
Kuehni C, Tissing WJ, Kremer LC. A new method to facili-
tate valid and consistent grading cardiac events in childhood 
cancer survivors using medical records. Plos ONE. 2014; 
9(7):e100432.
31. Gianinazzi ME, Rueegg CS, von der Weid NX, Niggli FK, 
Kuehni CE, Michel G, Swiss Paediatric Oncology G. Mental 
health - care utilization in survivors of childhood cancer and 
siblings: the Swiss childhood cancer survivor study. Support 
Care Cancer. 2014b; 22(2):339 - 49.
32. Gianinazzi ME, Essig S, Rueegg CS, von der Weid NX, Braz-
zola P, Kuehni CE, Michel G, Swiss Paediatric Oncology G. 
Information provision and information needs in adult sur-
vivors of childhood cancer. Pediatr Blood Cancer. 2014a; 
61(2):312 - 8.
33. Hauri DD, Spycher B, Huss A, Zimmermann F, Grotzer M, von 
der Weid N, Spoerri A, Kuehni CE, Roosli M, Swiss National 
C, the Swiss Paediatric Oncology G. Exposure to Radio - Fre-
quency Electromagnetic Fields From Broadcast Transmitters 
and Risk of Childhood Cancer: A Census - based Cohort 
Study. Am J Epidemiol. 2014; 179(7):843 - 51.
34. Shu X, Prochazka M, Lannering B, Schuz J, Roosli M, Tynes 
T, Kuehni CE, Andersen TV, Infanger D, Schmidt LS, Poulsen 
AH, Klaeboe L, Eggen T, Feychting M. Atopic conditions and 
brain tumor risk in children and adolescents  - an international 
case - control study (CEFALO). Ann Oncol. 2014; 25(4):902 - 8.
35. Terenziani M, Spinelli M, Jankovic D, Bardi E, Hjorth L, Haupt 
R, Michel G and Byrne J, on behalf of the PanCare Network. 
Practices of pediatric oncology and hematology providers re-
garding fertility issues: A European Survey. Pediatric Blood & 
Cancer. 2014; 61(11), 2054–2058.
36. Wengenroth L, Rueegg CS, Michel G, Essig S, Ammann RA, 
Bergstraesser E, Kuehni CE, Swiss Paediatric Oncology G. 
Life partnerships in childhood cancer survivors, their siblings, 
and the general population. Pediatr Blood Cancer. 2014; 
61(3):538 - 45.
 2013
37. Andersen TV, Schmidt LS, Poulsen AH, Feychting M, Roos-
li M, Tynes T, Aydin D, Prochazka M, Lannering B, Klaeboe 
L, Eggen T, Kuehni CE, Schmiegelow K, Schuz J. Patterns of 
exposure to infectious diseases and social contacts in early 
life and risk of brain tumours in children and adolescents: 
an International Case - Control Study (CEFALO). Br J Cancer. 
2013; 108(11):2346 - 53.
38. Gianinazzi ME, Rueegg CS, Wengenroth L, Bergstraesser E, 
Rischewski J, Ammann RA, Kuehni CE, Michel G, for Swiss 
Pediatric Oncology G. Adolescent survivors of childhood 
cancer: are they vulnerable for psychological distress? Psy-
chooncology. 2013c; 22(9):2051 - 8.
39. Hauri D, Spycher B, Huss A, Zimmermann F, Grotzer M, 
von der Weid N, Weber D, Spoerri A, Kuehni CE, Roosli M, 
Swiss National C, Swiss Paediatric Oncology G. Domestic ra-
don exposure and risk of childhood cancer: a prospective 
census - based cohort study. Environ Health Perspect. 2013; 
121(10):1239 - 44.
40. Hauri DD, Huss A, Zimmermann F, Kuehni CE, Roosli M, 
Swiss National C. Prediction of residential radon exposure 
of the whole Swiss population: comparison of model - based 
predictions with measurement - based predictions. Indoor 
Air. 2013; 23(5):406 - 16.
41. Rueegg CS, Gianinazzi ME, Michel G, von der Weid NX, 
Bergstraesser E, Kuehni CE, Swiss Paediatric Oncology G. Do 
childhood cancer survivors with physical performance lim-
itations reach healthy activity levels? Pediatr Blood Cancer. 
2013a; 60(10):1714 - 20.
42. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M, 
von der Weid NX, Michel G, Kuehni CE. Health - related qual-
ity of life in survivors of childhood cancer: the role of chronic 
health problems. J Cancer Surviv. 2013b; 7(4):511 - 22.
43. Satgé D, Stiller C, Rutkowski S, Bueren A, Lacour B, Som-
melet D, Nishi M, Massimino M, Garré M, Moreno F, Hasle 
33Swiss Childhood Cancer Registry Annual Report  2014/2015  Publications
H, Jakab Z, Greenberg M, Weid N, Kuehni CE, Zurriaga O, 
Vicente M - L, Peris - Bonet R, Benesch M, Vekemans M, Sul-
livan S, Rickert C. A very rare cancer in Down syndrome: 
medulloblastoma. Epidemiological data from 13 countries. 
J Neurooncol. 2013; 112(1):107 - 14.
44. Singer S, Gianinazzi ME, Hohn A, Kuehni CE, Michel G. 
General practitioner involvement in follow - up of childhood 
cancer survivors: a systematic review. Pediatr Blood Cancer. 
2013; 60(10):1565 - 73.
45. Zimmermann K, Ammann RA, Kuehni CE, De Geest S, Cig-
nacco E. Malnutrition in pediatric patients with cancer at di-
agnosis and throughout therapy: A multicenter cohort study. 
Pediatr Blood Cancer. 2013; 60(4):642 - 9.
 2012
46. Aydin D, Feychting M, Schuz J, Roosli M, team Cs. Child-
hood brain tumours and use of mobile phones: comparison 
of a case - control study with incidence data. Collaborators: 
Tynes T, Andersen TV, Schmidt LS, Poulsen AH, Johansen 
C, Prochazka M, Lannering B, Klæboe L, Eggen T, Jenni D, 
Grotzer M, Von der Weid N, Kuehni CE. Environ Health. 
2012; 11:35.
47. Christensen JS, Mortensen LH, Roosli M, Feychting M, Tynes 
T, Andersen TV, Schmidt LS, Poulsen AH, Aydin D, Kuehni CE, 
Prochazka M, Lannering B, Klaeboe L, Eggen T, Schuz J. Brain 
tumors in children and adolescents and exposure to animals 
and farm life: a multicenter case - control study (CEFALO). 
Cancer Causes Control. 2012; 23(9).
48. Essig S, von der Weid NX, Strippoli MPF, Rebholz CE, Michel 
G, Rueegg CS, Niggli FK, Kuehni CE. Health - related quali-
ty of life in long - term survivors of relapsed childhood acute 
lymphoblastic leukemia: The Swiss Childhood Cancer Survi-
vor Study. Plos ONE. 2012; 7(5):e38015.
49. Essig S, Skinner R, von der Weid NX, Kuehni CE, Michel G. 
Follow - up programs for childhood cancer survivors in Eu-
rope: a questionnaire survey. Plos ONE. 2012; 7(12):e53201.
50. Hauri DD, Huss A, Zimmermann F, Kuehni CE, Roosli M. A 
prediction model for assessing residential radon concentra-
tion in Switzerland. J Environ Radioact. 2012; 112:83 - 9.
51. Kuehni CE, Strippoli MP, Rueegg CS, Rebholz CE, Berg-
straesser E, Grotzer M, von der Weid NX, Michel G. Edu-
cational achievement in Swiss childhood cancer survivors 
compared with the general population. Cancer. 2012a; 
118(5):1439 - 49.
52. Rebholz CE, Spycher BD, Rueegg CS, Michel G, Ammann R, 
von der Weid NX, Kuehni CE. Clustering of health behaviours 
in adult survivors of childhood cancer and the general popu-
lation. Brit J Cancer. 2012; 107(2):234 - 42.
53. Rebholz CE, Kuehni CE, Strippoli MPF, Rueegg CS, Michel G, 
Hengartner H, Bergstraesser E, von der Weid NX. Alcohol 
consumption and binge drinking in young adult childhood 
cancer survivors: A report from the Swiss Childhood Cancer 
Survivor Study. Pediatric Blood Cancer. 2012; 58:256 - 64.
54. Rueegg CS, Michel G, Wengenroth L, von der Weid NX, 
Bergstraesser E, Kuehni CE. Physical performance limitations 
in adolescent and adult survivors of childhood cancer and 
their siblings. Plos ONE. 2012a; 7(10):e47944.
55. Rueegg CS, Rebholz CE, Michel G, Grotzer M, von der Weid 
NX, Kuehni CE. Daily physical activity and sport of adult sur-
vivors of childhood cancer and healthy control. Plos ONE. 
2012b; 7(4):e34930.
 2011
56. Aydin D, Feychting M, Schuz J, Andersen TV, Poulsen AH, 
Prochazka M, Klaeboe L, Kuehni CE, Tynes T, Roosli M. Pre-
dictors and overestimation of recalled mobile phone use 
among children and adolescents. Prog Biophys Mol Biol. 
2011; 107(3):356 - 61. Epub 2011 /09 /13.
57. Aydin D, Feychting M, Schüz J, Andersen TV, Poulsen AH, 
Prochazka M, Klaebo L, Kuehni CE, Tynes T, Roeoesli M. Im-
pact of random and systematic recall errors and of selection 
bias in case - control studies on mobile phone use and brain 
tumors in adolescents (CEFALO study). Bioelectromagnetics. 
2011; 32:396 - 407.
58. Aydin D, Feychting M, Schüz J, Tynes T, Andersen TV, 
Schmidt LS, Poulsen AH, Johansen C, Prochazka M, Lanner-
ing B, Klaeboe L, Eggen T, Jenni D, Grotzer M, Von der Weid 
NX, Kuehni CE, Roeoesli M. Mobile phone use and brain tu-
mors in children and adolescents: a multicenter case - control 
study. J Natl Cancer Inst. 2011; 1264 - 76.
59. Marquis A, Strippoli MPF, Spycher BD, Rebholz CE, von der 
Weid NX, Kuehni CE. Paracetamol, NSAIDS and risk of asth-
ma in adult survivors of childhood cancer. J Allergy Clin Im-
munol. 2011; 127:270 - 2.
60. Michel G, Kuehni CE, Rebholz CE, Zimmermann K, Eiser C, 
Rueegg CS, von der Weid NX. Can health beliefs help ex-
plaining attendance to follow - up care? The Swiss Childhood 
Cancer Survivor Study. Psychooncology. 2011; 20:1034 - 43.
61. Rebholz CE, Reulen RC, Toogood A, Frobisher C, Lancashire 
ER, Winter DL, Kuehni CE, Hawkins M. Health care utilization 
of long - term survivors of childhood cancer: the British Child-
hood Cancer Survivor Study. J Clin Oncol. 2011; 29:4181 - 8.
62. Rebholz CE, von der Weid NX, Michel G, Niggli F, Kuehni 
CE. Follow - up care among long - term childhood cancer 
survivors: a report from the Swiss childhood cancer survivor 
study. Eur J Cancer. 2011; 41:221 - 9.
63. Spycher BD, Feller M, Zwahlen M, Röösli M, von der Weid 
NX, Hengartner H, Egger M, Kuehni CE. Childhood cancer 
and nuclear power plants in Switzerland: a census - based 
cohort study. Int J Epidemiol. 2011; 40:1247 - 60.
 2010
64. Adam M, von der Weid NX, Michel G, Zwahlen M, Lutz JM, 
Probst - Hensch N, Niggli F, Kuehni CE. Access to specialized 
pediatric cancer care in Switzerland. Pediatr Blood Cancer. 
2010; 54:721 - 7.
65. Feller M*, Adam M*, Zwahlen M, Brazzola P, Niggli F, Kuehni 
CE. Family characteristics as risk factors for childhood acute 
lymphoblastic leukemia. *joint first authorship. PLo One. 
2010; 5; e13156.
66. Marquis, A, Kuehni CE*, Strippoli MPF, Kühne T, Brazzola 
P, for the Swiss Pediatric Oncology Group (SPOG). Sperm 
analysis of patients after successful treatment of childhood 
acute lymphoblastic leukemia with chemotherapy only. *cor-
responding author. Pediatr Blood Cancer. 2010; 55:208 - 10.
34
67. Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, 
Kuehni CE. Psychological distress in adult survivors of child-
hood cancer: the Swiss Childhood Cancer Survivor Study. J 
Clin Oncol. 2010; 28:1740 - 8.
 2009
68. Spycher BD, Minder CE, Kuehni CE. Multivariate modelling 
of responses to conditional items: New possibilities for latent 
class analysis. Stat Med. 2009; 28:1927 - 39.
 2008
69. Michel G, von der Weid N, Zwahlen M, Redmond S, Strip-
poli MPF, Kuehni CE. Incidence of childhood cancer in Swit-
zerland: the Swiss Childhood Cancer Registry. Pediatr Blood 
Cancer. 2008; 50:46 - 51.
 2007
70. Michel G, von der Weid N, Zwahlen M, Adam M, Rebholz 
CE, Kuehni CE. The Swiss Childhood Cancer Registry: ra-
tionale, organisation and results for the years 2001 - 2005. 
Swiss Med Wkly. 2007; 137:502 - 9. 
71. Röösli M, Michel G, Kuehni CE, Spoerri A. Cellular telephone 
use and time trends in brain tumour mortality in Switzerland 
from 1969 to 2002. Eur J Cancer Prev. 2007; 16:77 - 82.
5.2 Editorials, commentaries and author replies  
 (Peer reviewed journals)
 2015
72. Lupatsch JE, Egger M, Kuehni CE, Spycher BD. The authors’ 
reply: Population mixing and childhood leukaemia. Eur J Epi-
demiol. 2015c; 30(12):1333 - 4.
73. Spycher BD, Roosli M, Egger M, Kuehni CE. “Author’s 
Comment on ‘Background Ionizing Radiation and the Risk 
of Childhood Cancer: A Census - Based Nationwide Cohort 
Study’”. Environ Health Perspect. 2015b; 123(8):A198 - 9.
74. Spycher BD, Roosli M, Egger M, Kuehni CE. Response to 
“Comment on ‘Background Ionizing Radiation and the Risk 
of Childhood Cancer: A Census - Based Nationwide Cohort 
Study’”. Environ Health Perspect. 2015c; 123(8):A200 - 1.
 2012
75. Spycher BD, Kuehni CE, Zwahlen M, Egger M on behalf of 
the Swiss National Cohort Study Group and the Swiss Paedi-
atric Oncology Group. Authors’ response to: Childhood can-
cer and nuclear power plants in Switzerland: a census - based 
cohort study. Int J Epidemiol. 2012; 41: 321 - 322.
 2006
76. Kuehni CE, Zwahlen M. Commentary: Numerous, heteroge-
neous and often poor – the studies on childhood leukaemia 
and socioeconomic status. Int J Epidemiol. 2006; 35:384 - 5.
5.3 Reviews (Peer reviewed journals) 
 2015
77. Bhatia S, Armenian SH, Armstrong GT, van Dulmen - den Bro-
eder E, Hawkins MM, Kremer LC, Kuehni CE, Olsen JH, Ro-
bison LL, Hudson MM. Collaborative Research in Childhood 
Cancer Survivorship: The Current Landscape. J Clin Oncol. 
2015; 33(27):3055 - 64.
78. Winther JF, Kenborg L, Byrne J, Hjorth L, Kaatsch P, Kremer 
LC, Kuehni CE, Auquier P, Michel G, de Vathaire F, Haupt 
R, Skinner R, Madanat - Harjuoja LM, Tryggvadottir L, We-
senberg F, Reulen RC, Grabow D, Ronckers CM, van Dul-
men - den Broeder E, van den Heuvel - Eibrink MM, Schindler 
M, Berbis J, Holmqvist AS, Gudmundsdottir T, de Fine Licht S, 
Bonnesen TG, Asdahl PH, Bautz A, Kristoffersen AK, Himmer-
slev L, Hasle H, Olsen JH, Hawkins MM. Childhood cancer 
survivor cohorts in Europe. Acta Oncol. 2015; 54(5):655 - 68.
 2014
79. Kuehni C, Spycher BD. Nuclear power plants and childhood 
leukaemia: lessons from the past and future directions. Swiss 
Med Wkly. 2014; 144:w13912.
80. Laurier D, Grosche B, Auvinen A, Clavel J, Cobaleda C, De-
hos A, Hornhardt S, Jacob S, Kaatsch P, Kosti O, Kuehni C, 
Lightfoot T, Spycher B, Van Nieuwenhuyse A, Wakeford R, 
Ziegelberger G. Childhood leukaemia risks: from unexplained 
findings near nuclear installations to recommendations for 
future research. J Radiol Prot. 2014; 34(3):R53 - 68.
 2012
81. Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, 
Niggli FK, Egger M, von der Weid NX. Cohort Profile: The 
Swiss Childhood Cancer Survivor Study. Int J Epidemiol. 
2012b; 41(6):1553 - 64. Epub 2012 /06 /28.
 2008
82. Adam M, Rebholz C, Egger M, Zwahlen M, Kuehni CE. Child-
hood Leukaemia and Socioeconomic Status: what is the evi-
dence? Radiat Prot Dosim. 2008; 132:246 - 54. 
35Swiss Childhood Cancer Registry Annual Report  2014/2015  Publications
5.4 Publications (other journals)
Schweizer Krebsbulletin
 2016
83.  Lupatsch JE, Kreis C, Niggli F, Kuehni CE, Spycher B. 2016. 
Ursachen von Krebs bei Kindern: Was verrät der Wohnort? 
Schweizer Krebsbulletin 2016a; 36(01): 29 - 33.
 2014
84. Wengenroth L, Schindler M, Kuonen R, Kuehni CE. Krebs als 
Kind oder Teenager: das Leben danach. Schweizer Krebsbul-
letin 2014; 4: 292 - 295.
85. Michel G, von der Weid NX. Nachsorge nach Krebs im 
Kindesalter – Pläne für die Schweiz. Schweizer Krebsbulletin 
2014; 4: 296 - 298
 2013
86. Kuehni CE, Mitter V, Niggli F, von der Weid NX. Die Rolle 
des Kinderkrebsregisters unter dem geplanten Krebsregis-
trierungsgesetz: Chancen und Risiken. Schweizer Krebsbul-
letin 2013; 3:213 - 216.
 2012
87. Niggli F, Kuehni CE, Lamontagne - Müller S. Seltene Krebser-
krankungen – das tägliche Brot der pädiatrischen Onkologie. 
Schweizer Krebsbulletin. 2012; 4. 309 - 10. 
88. Michel G. Nachsorge nach Krebs im Kindesalter. Schweizer 
Krebsbulletin. 2012; 3: 212 - 213.
 2010
89. Kuehni CE. The Swiss Childhood Cancer Registry: from caus-
es to outcomes. Schweizer Krebsbulletin. 2010; 2:129 - 130.
 2009
90. Kuehni CE, Feller M, Egger M. Response to: Sufficient sta-
tistical power for CANUPIS? Bulletin suisse du cancer. 2009; 
4.09:301.
 2008
91. Kuehni CE, von der Weid NX, Hengartner H, Niggli F, Röösli 
M, Huss A, Feller M, Egger M. CANUPIS – Childhood Cancer 
  and Nuclear Power Plants in Switzerland. Schweizer Krebs-
  bulletin. 2008; 28: 264 - 266.
92. von der Weid NX, Kuehni CE. Le Registre Suisse du Cancer 
de l’Enfant: premier Registre du Cancer national. Information 
de la communauté médicale quant à la nouvelle situation 
concernant la protection des données. Bulletin des médecins 
suisses. 2008; 89:117 - 9.
Other
 2013
93. Mitter V, Michel G. Krebs bei Kindern. Ein Überblick aus dem 
Schweizer Kinderkrebsregister. Onkologiepflege 1; 5 - 8.
94. Ruegg CS, Gianinazzi ME, Michel G. Psychosoziale Spätfol-
gen nach Kinderkrebs – Eine Langzeitstudie des Schweizer 
Kinderkrebsregisters. Newsletter Schweizerische Gesellschaft 
für Psychoonkologie. 21; 5 - 8.
95. Kuehni CE, Michel G, Egger M, Zwahlen M, Beck Popovic M, 
Nigglie F, von der Weid NX. Das Schweizer Kinderkrebsregis-
ter: Erfahrungen als nationales Krebsregister. Schweizerische 
Ärztezeitung 2013; 94: 327.
96. Kuehni CE, Niggli FK. Endlich ein nationales Krebsregis-
trierungsgesetz für Kinder und Erwachsene. Schweizerische 
Ärztezeitung 2013; 94: 160.
 2008
97. Michel G. Nachsorge nach Krebs im Kindesalter – ein neues 
Feld für Pflege?. Onkologiepflege 2011; 3: 20 - 23.
98. Kuehni CE, von der Weid NX. Das Schweizer Kinderkrebs-
register als erstes nationales Krebsregister: Information der 
Ärzteschaft zur neuen Datenschutzsituation. Schweizerische 
Aerztezeitung. 2008; 89:117 - 9.
99. Kuehni CE, von der Weid NX. Das Schweizer Kinderkrebs-
register als erstes nationales Krebsregister: Information der 
Ärzteschaft zur neuen Datenschutzsituation. Paediatrica. 
2008; 19:53 - 5.
100. von der Weid NX, Kuehni CE. Le Registre Suisse du Cancer 
de l’Enfant: premier Registre du Cancer national. Information 
de la communauté médicale quant à la nouvelle situation 
concernant la protection des données. Paediatrica. 2008; 
19:50 - 2.
 2007
101. Kuehni CE. Children’s health and the environment. A global 
perspective (Book review). Paediatrica 2007; 15:13 - 28.
36
5.5 Reports
Annual Reports SCCR
 2015
102. Schindler M, Mitter V, Pfeiffer V, Redmond S, Wölfli P, Kuonen 
R, Sommer G, Spring M, Singh P, Michel G, Kuehni CE, The 
Swiss Childhood Cancer Registry. Annual Report 2013 /2014. 
Berne: Dept. of Social and Preventive Medicine, University of 
Bern; March 2015.
 2013
103. Mitter V, Michel G, Wölfli P, Gianinazzi M, Ruegg CS, Som-
mer G, Hau E, Kuehni CE, The Swiss Childhood Cancer Reg-
istry. Annual Report 2011 /2012. Berne: Dept. of Social and 
Preventive Medicine, University of Bern; Feb 2013.
 2011
104. Mitter V, Michel G, Strippoli MPF, Rebholz CE, Rueegg CS, 
Viehmann G, Reck M, Niggli F, Hengartner H, von der Weid 
NX, Kuehni CE. The Swiss Childhood Cancer Registry. Annu-
al Report 2009 /2010. Bern: Dept. of Social and Preventive 
Medicine, University of Bern; April 2011.
 2009
105. Kuehni CE, Michel G, Pyrlic M, Strippoli MP, Adam M, Reb-
holz C, Rueegg C, Viehmann G, Reck M, Niggli F, Hengartern 
H, von der Weid N. The Swiss Childhood Cancer Registry. 
Annual Report 2007 /2008. Berne: Dept. of Social and Pre-
ventive Medicine, University of Bern; June 2009.
 2007
106. Michel G, von der Weid NX, Adam M, Rebholz G, Zwahlen 
M, Kuehni CE. The Swiss Childhood Cancer Registry. Annu-
al Report 2005 /2006. Berne: Dept. Of Social and Preventive 
Medicine, University of Bern; May 2007.
 2005
107. Kuehni CE, Michel G, Sturdy M, Redmond S, Zwahlen M, von 
der Weid N. The Swiss Childhood Cancer Registry. Annual 
Report 2004. Bern: Dept. of Social and Preventive Medicine, 
University of Bern; December 2005.
Other Reports
 2016
108. Arndt V, Feller A, Hauri D, Heusser R, Junker C, Kuehni CE, 
Lorenz M, Pfeiffer V, Roy E, Schindler M. Schweizerischer 
Krebsbericht 2015 – Stand der Entwicklungen. Bundesamt 
für Statistik (BFS); Neuchâtel 2016.
 2011
109. Wyss N, Pury P, Strippoli MPF, Lutz JM, Bouchardy C, Kuehni 
CE, Junker C. Krebs in der Schweiz – Stand und Entwicklung 
von 1983 bis 2007. Bundesamt für Statistik (BFS); Neuchâtel 
2011.
 2005
110. Michel G, Sturdy M, Zwahlen M, Strippoli MPF, von der Weid 
N, Kuehni CE. Validating date and cause of death informa-
tion in the Swiss Childhood Cancer Registry against death 
certificate information from the Swiss Federal Office of Statis-
tics. Bern: Dept. of Social and Preventive Medicine, University 
of Bern; December 2005.
37Swiss Childhood Cancer Registry Annual Report 2014/2015  Appendix: Classification of cancer diagnoses
International Classification of Childhood Cancer  - 
ICCC - 3
The third edition of the International Classification of 
Childhood Cancer (ICCC - 3) represents the standard for pre-
sentation of international data on childhood cancer incidence 
and survival. It applies the rules, nomenclature and codes (mor-
phology, topography and behaviour) of the ICD - O - 3. ICCC - 3 
categories are defined in conformity with international classifi-
cations of the pathology and genetics of childhood cancers. In 
the ICCC - 3, three hierarchical levels have been developed: lev-
el one consists of 12 main diagnostic groups and level two of 
47 diagnostic subgroups. These two levels of the ICCC - 3 allow 
standardised comparison of the broad categories of childhood 
tumours. Level three, an optional «extended» classification, 
comprises two to eleven divisions of selected diagnostic sub-
groups. The division of some diagnostic subgroups, e.g. leu-
kaemia and Non - Hodgkin lymphomas, reflects the availability 
of detailed cytogenetic or molecular information that permits 
homogeneous groups of tumours to be distinguished within 
them and thus allows their separate study. The Swiss childhood 
cancer registry (SCCR) uses level one to three. Only malignant 
neoplasms are classified in ICCC - 3, with the exception of 
non - malignant intracranial and intraspinal tumours. Tumours 
known to occur only rarely in young patients are also included 
in ICCC - 3. The ICCC - 3 is used if data are compared with other 
childhood cancer registries.
International Statistical Classification of Diseases for 
Oncology  - ICD - O - 3
The third edition of the International Statistical Classifica-
tion of Diseases for Oncology (ICD - O - 3) has been developed 
by a working group hosted by the International Association of 
Research in Cancer (IARC) and WHO. The morphology code for 
neoplasm has been revised, especially for lymphomas and leu-
kaemia. In contrast to the International Classification of Diseas-
es, 10th revision (ICD - 10), ICD - O - 3 uses only one set of four 
characters for topography (based on the malignant neoplasm 
section of ICD - 10). The topography code remains the same for 
all neoplasms of that site. The behaviour code is incorporated 
as the fifth digit in the morphology field. It identifies whether 
the tumour is malignant, benign, of uncertain or unknown be-
haviour, in situ, presumed to be primary or secondary. For all 
tumours diagnosed since 1st January 2014 the SCCR uses the 
2011 updates to ICD - O - 3 which include new terms, codes 
and behaviour combinations. This allows e.g. B lymphoblas-
tic leukaemias to be further classified according to their exact 
cytogenetic and molecular characteristics, which are relevant 
for disease prognosis. ICD - O - 3 is used to compare data with 
general cancer registries.
International Statistical Classification of Diseases 
and Related Health Problems  - ICD - 10
The International Statistical Classification of Diseases and 
Related Health Problems (ICD) permits the systematic record-
ing, analysis, interpretation and comparison of mortality and 
morbidity data collected in different regions and at different 
time periods. The ICD has become the international standard 
diagnostic classification for all general epidemiological purpos-
es. The ICD - 10 classification comprises three volumes: Volume 
1 contains the main classifications; Volume 2 provides guid-
ance for users of the ICD; and Volume 3 is the alphabetical in-
dex to the classification. Classification is divided into 21 chap-
ters. The first character of the ICD code is a letter. Each letter 
is associated with a particular chapter, e.g. the letter D is used 
in both chapter II «Neoplasms» and chapter III «Diseases of the 
blood and blood - forming organs and certain disorders involv-
ing the immune mechanism». The topography code in Volume 
3 describes the site and the behaviour of the neoplasm: malig-
nant, secondary or metastatic, in situ, benign or of unknown 
behaviour. The morphology codes listed in Volume 1 are the 
same as those used in the special adaptation of the ICD for 
oncology, the ICD - O97.
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